

BIOHK2023

香港國際生物科技論壇暨展覽

DISCOVER THE LIMITLESS
POTENTIAL OF HONG KONG'S
BIOTECH ECOSYSTEM

CONFERENCE

DAY THREE

Friday September 15

Order of advertisements will be different on the printed version



構建萬物互聯的智能世界

華為雲EI醫療智能體

全棧、開放、專業的醫療AI研發平台



BIOHK2023
SILVER SPONSOR

華為雲醫療智能體（EIHealth）覆蓋基因組、臨床資料研究和藥物研發三個領域，以全民健康為中心，推進人工智能與醫療健康相結合，提升醫療健康的服務能力和普惠水準，以華為強大的算力、存儲和AI演算法，賦能基因產業、疾病診斷和製藥領域。




基因組自動建模工具AutoGenome

利用AutoML等技術對基因組學資料建模分析，僅需5行代碼就可以完成基因組資料建模、訓練、準確性評估、預測和模型解釋。



藥物虛擬篩選

可根據靶點蛋白和小分子藥物的3D結構，計算蛋白與藥物之間的結合能量，並且依託雲端大算力從成千上百萬的小分子庫中快速篩選出與蛋白結合最緊密的候選藥物。



技術受限

數字主權
完全控制



數年 > 1個月
先導藥研發週期



診療效率 > 30%



掃碼進入華為雲官網“EI醫療智能體”頁面
了解更多詳情，歡迎撥打銷售熱線：+852 5700 0516

華為雲 一切皆服務

08:30	EVENT REGISTRATION 活动登记			
	BIOHK AUDITORIUM			
09:00 - 09:30	IPSCS-BASED REGENERATIVE MEDICINE, DRUG DEVELOPMENT, AND CLINICAL TRIAL FOR NEUROLOGICAL DISORDERS KEYNOTE SESSION: PROF. HIDEYUKI OKANO 岡野荣之 (KEIO UNIVERSITY SCHOOL OF MEDICINE) 主讲嘉宾: 岡野荣之教授 (庆应义塾大学医学院研究生院院长)			
09:30 - 10:00	BEYOND IMMUNOTHERAPY FOR CANCER TREATMENT: EMERGING STRATEGIES KEYNOTE SESSION: PROF. TAK WAH MAK 麦德华 (THE HONG KONG UNIVERSITY, INNOHK) 主讲嘉宾: 麦德华教授 (香港大学肿瘤及免疫学研究中心总监, 英国皇家学会院士)			
	BIOHK AUDITORIUM	INNOVATION GALLERIA	TECHNOLOGY HALL	LOCI SQUARE
10:00 - 11:00	SPONSOR: PHARMABOARDROOM CAR-T THERAPY CAR-T细胞疗法 10:00-11:00 Moderator: Ms. Diana Viola (PharmaBoardroom) 主持人: Diana Viola女士 (PharmaBoardroom) Dr. Azucena Gonzalez (Hospital Clinic de Barcelona) Azucena Gonzalez 教授 (Hospital Clinic de Barcelona) Dr. Lin Yang (PersonGen BioTherapeutics) 杨林博士 (博生医药) Dr. Gina Jiang (HKOB) 江宜豪博士 (香港生物科技研究院) Dr. Stephen Liu (IST PHI Therapeutics) Stephen Liu 博士 (伊尊生物)	SPONSOR: HUAWEI CLOUD 赞助商: 华为云 BIG DATA AND AI IN HEALTHCARE 医疗保健中的大数据和人工智能 10:00-11:25 华为云盘古大模型医疗行业应用实践 Mr. Wei Sing (HUAWEI CLOUD) 桑伟先生 (华为云) An Introduction of CP AI Biotech Works in Food, Health and Sustainability Mr. John Yue Jun Jiang (CP Group) John Yue Jun Jiang 先生 (CP Group 正大集团) Future Opportunities at the Intersection of Modelling, AI, Supercomputing and Clinical Trials Dr. Christopher Morton (ELEM Biotech SL) Christopher Morton 博士 How AI is Transforming Drug Discovery & Aging Research Dr. Frank Pun (Insilico Medicine) Frank Pun 博士 (Insilico Medicine 英科智能) Patient care through AI-powered predictive solutions Dr. Echo Chen (LUCA Healthcare) 陈思博士 (Luca Healthcare)	SEARCHING FOR THE NEXT LIFE SCIENCE UNICORN 寻找下一个生命科学独角兽 10:00-11:00 Chair: Mr. Da Liu (CR-CP Life Sciences Fund) 主席: 柳达博士 (华冠正大生命科学基金) Mr. Nigel Yip (Simaomics) 叶永基先生 (圣诺医药) Mr. Francis Cao (ImxMed) 曹飞先生 (应世生物联合) Mr. Simon Hua (China Finance Strategies Investment Holdings Ltd.) Mr. Simon Hua 先生 (中国金融策略投资控股) Mr. Martin Law (MIRKES Hong Kong) 罗文达先生 (MIRKES Hong Kong Ltd)	SPONSOR: ASTRAZENECA 赞助商: 阿斯利康 BUILDING INNOVATIVE ECOSYSTEM FOR INTERNATIONAL STARTUPS 10:00-11:00 How AstraZeneca Can Boost An Innovation Ecosystem in Hong Kong Ms. Shan Wu (AstraZeneca) Shan Wu女士 (阿斯利康) Capital Market Review and Healthcare Industry Opportunities Ms. Rongrong Guo (CICC) Rongrong Guo女士 (中金公司)
11:00 - 11:30	EXPLORING THE MARVELS OF THE BRAIN 探索大脑的奇迹 11:00-13:00 Chair 主席: Dr. Charles Hu (Ryoden Medical Holdings Ltd.) 主席: 胡正志博士 (康电医疗) Neurogenesis for Stroke, Spinal Cord Injury, and Cardiac Arrest Keynote: Prof. Wise Young (Rutgers, State University of New Jersey) 主讲嘉宾: 杨咏威教授 (Mononuclear Therapeutics) Targeting Receptors for Brain Diseases Prof. Wei Chen (Tiantan Hospital) 陈伟教授 (首都医科大学北京天坛医院) How Does the Brain Regain Consciousness from Anesthesia? Prof. Xuejun Song (Southern University of Science and Technology) 宋学军教授 (南方科技大学) Breakthrough Therapeutics for Brain Disorders Mr. Coach Wei (Neural Galaxy) 魏可成先生 (优脑银河) 脑机接口: 让大脑连接未来 Mr. Lei Peng (NeuroKess) 彭雷先生 (脑虎科技) 基于脑机接口的神经调控技术及产业化 Dr. Peng Cao (Genlight) 曹鹏博士 (佳量医疗) A Breakthrough in Implantable Photomedicine Dr. Percy Lui (Incando Therapeutics) Percy Lui 博士 (Incando Therapeutics)			
11:30 - 12:15	INNOVATIVE BIOPHARMACEUTICAL PRODUCTION 创新药物生产 11:25-12:10 核酸疫苗/药物连续生产工艺实现及法规要求 Dr. Tao Kang 覃涛博士 Tao Kang 先生 (香港信达创新中心) CRO及CDMO能高特异性基因疗法开发与生产 Dr. Cole Cheng 郑毅东博士 (VectorBuilder 云舟)			
12:15 - 13:00	CLINICAL TRIALS IN HONG KONG: EXPERIENCE AND OPPORTUNITIES 香港临床试验: 经验与机遇 12:15-13:00 Moderator: Ms. Diana Viola (PharmaBoardroom) 主持人: Diana Viola女士 (PharmaBoardroom) Mr. Henry Yau (HK Clinical Trials Center) 郑广先生 (香港临床研究中心) Dr. Karen Chu (Harvest Integrated Research Organisation) Karen Chu 博士 (上海贺维斯医药科技有限公司) Mr. Danny Yeung (Gilead Sciences) Danny Yeung 博士 (吉利德科学)			
13:00 - 14:00	LUNCH BREAK			
14:00 - 14:30	BATTLE AGAINST THE INFECTIOUS TITANS 与感染性疾病巨人的战斗 14:00-17:20 Diagnostic Stewardship: Strategies to Enhancing Antimicrobial Prescribing Chair: Prof. Margaret Ip (Chinese University of Hong Kong) 主席: 叶曙曜教授 (香港中文大学) Hepatitis B Control: Illustrating the Impact of Collaboration Keynote: Prof. Pei-Jer Chen (National Taiwan University and Hospital) 主讲嘉宾: 陈培哲教授 (台湾大学医学院) A Novel Urinary DNA Isolation Method to Improve HPV Detection and Genotyping Chair: Ricky Chu (PHASE Scientific) 招彦杰博士 (相达生物科技) Long COVID-19 Symptoms in Cohort and Case-control Studies: A Systematic Review Dr. Dexing Zhang (Chinese University of Hong Kong) 张德香博士 (香港中文大学公共卫生学院) Data Science Approaches to Infectious Disease Surveillance and Control Dr. Qingpeng Zhang (The University of Hong Kong) 张清鹏博士 (香港大学公共卫生数据科学研究院) Landscape Overview of mRNA Therapeutics Dr. Jijun Yuan (Aogen Biosciences) 袁纪军博士 (艾博生物) 基于重组病毒载体体系的生物药开发生物药 Dr. Jiasheng Song (Difference Biological Tech) 宋家升博士 (道福瑞生生物科技)			
14:30 - 15:00	THE STATE OF EMERGING BIOTECHS 初创生物科技公司的前景 16:00-17:00 Moderator: Mr. Yuyao Peng (China Renaissance Securities) 主持人: 彭宇瑶先生 (中银证券) Mr. Mikko Taiti (Delta Partners) Mikko Taiti 先生 (Delta Capital) Mr. Andrew Ng (Private Equity at VMS Group) Andrew Ng 先生 (VMS Group) Mr. Sammi Wong (HKSTP Capital) Sammi Wong 先生 (香港科技园资本) Ms. Helen Chen (LEK) 陈玮女士 (艾意斯香港) Dr. Dong Li (Hong Kong APX Capital) 董利博士 (香港亚细亚资本)			
15:00 - 15:30	BIOTECH CAPITAL MARKETS IN HK AND GBA 香港和大湾区的生物科技资本市场 15:00-16:00 Chair 主席: Mr. Vijay Karwal (AffaMed Therapeutics) Vijay Karwal 先生 (赛诺医疗) Mr. Samuel Thong (Goldman Sachs) 童敦先生 (高盛集团) Mr. Andrew Ng (VMS Group) Andrew Ng 先生 (VMS Group) Mr. Sammi Wong (HKSTP Capital) Sammi Wong 先生 (香港科技园资本) Ms. Helen Chen (LEK) 陈玮女士 (艾意斯香港) Dr. Dong Li (Hong Kong APX Capital) 董利博士 (香港亚细亚资本)			
15:30 - 16:00	THE PRECISION MEDICINE ERA 精准医疗时代 15:30-17:30 Chair 主席: Dr. Desmond Hau (Pangenia) 主席: 侯国宝博士 (Pangenia) Moderator: Dr. Jay Dong (UltraDx) 主持人: 董耀博士 (UltraDx) Cancer Screening by Circulating DNA Analysis Keynote: Prof. Allen Chan (Center for Novosciats) 主讲嘉宾: 陈君耀教授 (创新诊断科技中心) Multi-cancer early detection via protein tumor markers and artificial intelligence Dr. Mao Miao (Seekin Inc.) 茅才博士 (思康医疗科技有限公司) CARDIYON – A Novel Biotech Solution to Reduce the Risk of Cardiovascular Diseases Dr. Vinca Gao (Govita Tech Ltd.) 高蔚新博士 (健科国际股份有限公司)			
16:00 - 16:30	“TOP 5 TO WATCH” PITCHING COMPETITION 项目交流会大赛 前五名评选 GREATER BAY BIOTECHNOLOGY LIMITED HAPLOX BIOTECH LUCY BIOTECH INSURATA LIMITED TCRCURE BIOPHARMA TECHNOLOGY JUPITER NEUROSCIENCES, INC LADWARE SINGAPORE PTE. LTD META PHARMACEUTICALS NAF PHARMA LOGISTICS LTD NEUROPIX PROVECTUS THERAPEUTICS RAPAFUSYN PHARMACEUTICALS AXIBO 瑞健生命科学研究院 TROMSO NUTRITION TECHNOLOGIES (HK.) LTD (RÖMEGA 挪威鱼肝油) TSINCKE BIOTECH TUNCEK CRO WWCPA ZENKTAGZHEJANG TECHNOLOGY DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD 浙江迪福润丝生物科技有限公司 北京擎科生物科技股份有限公司BEIJING TSINCKE BIOTECH CO., LTD. 十度生物科技有限公司 希毅医学 株式会社EKEI LABS 萃媛			
16:30 - 17:00	“TOP 5 TO WATCH” PITCHING COMPETITION 项目交流会大赛 前五名评选 GREATER BAY BIOTECHNOLOGY LIMITED HAPLOX BIOTECH LUCY BIOTECH INSURATA LIMITED TCRCURE BIOPHARMA TECHNOLOGY JUPITER NEUROSCIENCES, INC LADWARE SINGAPORE PTE. LTD META PHARMACEUTICALS NAF PHARMA LOGISTICS LTD NEUROPIX PROVECTUS THERAPEUTICS RAPAFUSYN PHARMACEUTICALS AXIBO 瑞健生命科学研究院 TROMSO NUTRITION TECHNOLOGIES (HK.) LTD (RÖMEGA 挪威鱼肝油) TSINCKE BIOTECH TUNCEK CRO WWCPA ZENKTAGZHEJANG TECHNOLOGY DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD 浙江迪福润丝生物科技有限公司 北京擎科生物科技股份有限公司BEIJING TSINCKE BIOTECH CO., LTD. 十度生物科技有限公司 希毅医学 株式会社EKEI LABS 萃媛			
17:00 - 17:30	“TOP 5 TO WATCH” PITCHING COMPETITION 项目交流会大赛 前五名评选 GREATER BAY BIOTECHNOLOGY LIMITED HAPLOX BIOTECH LUCY BIOTECH INSURATA LIMITED TCRCURE BIOPHARMA TECHNOLOGY JUPITER NEUROSCIENCES, INC LADWARE SINGAPORE PTE. LTD META PHARMACEUTICALS NAF PHARMA LOGISTICS LTD NEUROPIX PROVECTUS THERAPEUTICS RAPAFUSYN PHARMACEUTICALS AXIBO 瑞健生命科学研究院 TROMSO NUTRITION TECHNOLOGIES (HK.) LTD (RÖMEGA 挪威鱼肝油) TSINCKE BIOTECH TUNCEK CRO WWCPA ZENKTAGZHEJANG TECHNOLOGY DIFFERENCE BIOLOGICAL TECHNOLOGY CO.,LTD 浙江迪福润丝生物科技有限公司 北京擎科生物科技股份有限公司BEIJING TSINCKE BIOTECH CO., LTD. 十度生物科技有限公司 希毅医学 株式会社EKEI LABS 萃媛			

KEYNOTE ADDRESS

Friday, September 15 | 09:00 AM - 10:00 AM (GMT+8)

09:00 - 09:30	KEYNOTE SESSION: PROF. HIDEYUKI OKANO , CHAIR OF THE DEPARTMENT OF PHYSIOLOGY, KEIO UNIVERSITY SCHOOL OF MEDICINE iPSCs-based Regenerative Medicine, Drug Development, and Clinical Trial for Neurological Disorders
09:30 - 10:00	KEYNOTE SESSION: PROF. TAK WAH MAK , DIRECTOR, CENTRE OF ONCOLOGY AND IMMUNOLOGY, THE UNIVERSITY OF HONG KONG Beyond Immunotherapy for Cancer Treatment: Emerging Strategies

Sponsored by



BIOHK2023 PLATINUM SPONSOR

BOOTH NO. 3D-B4

海康生命科技
HAIKANG LIFE

BioRadar® System

Platform for comprehensive detection of invisible pathogens

系統臨床
產品管線



sirnaomics

Advancing RNAi Therapeutics

應用小核酸技術創製新藥的開拓者

A Leading RNAi Therapeutic Company
with Significant Presence in Both China & USA

創新引領 • 全球視野 • 關注病患

Innovation, Global Vision, Patient-centered

抗腫瘤、醫學美容及抗凝治療等

多項臨床研究已在美國及亞洲地區展開



聖諾醫藥官網



聖諾醫藥公眾號



聖諾醫藥(美國)
Sirnaomics, Inc

Sirnaomics, 廣州

Sirnaomics, 蘇州

Sirnaomics, 香港



Hideyuki Okano 岡野栄之

Professor and Chair

Department of Physiology, Keio University School of Medicine

He received M.D. in Physiology from Keio University in 1983. After he obtained a Ph.D. degree in Molecular Biology of Myelin-related genes and myelin deficient mutant mice from Keio University in 1988, he held a post-doctoral position at Dr. Craig Montell's Lab at Johns Hopkins University School of Medicine. He was appointed full professor at Tsukuba University School of Medicine in 1994, Osaka University School of Medicine in 1997, and returned to Keio University Medical School in 2001 as a full professor of Physiology. He has been conducting basic research in the field of regenerative medicine including neural stem cells and iPS cells, spinal cord injury, developmental genetics, and RNA binding proteins. His lab was the first in the world to successfully generate transgenic marmosets with germline transmission. His gene modification techniques can be used in a variety of non-human primates.

He has been awarded a number of awards and honors including the Medal with Purple Ribbon in 2009, the first prize of the 51st Erwin von Bälz Prize in 2014, and the Uehara Prize in 2022. He aims to establish and provide patient-specific iPS cells and genetically modified non-human primate models for neuroscience research and to explore the pathogenic mechanisms of neurological/psychiatric disorders. Currently, he is the leader of the Brain Project in Japan (Brain/MINDS) and the President of the Japanese Society for Regenerative Medicine. In 2022, he joined the Faculty of Massachusetts Institute of Technology (MIT, McGovern Institute) as a Visiting Professor. He was elected as the Vice President of the ISSCR in 2023 and his term began on July 1, 2023.

深圳市生命科学行业协会 Shenzhen Life Science Industry Association

深圳市生命科学行业协会简介

深圳市生命科学行业协会（英文名：Shenzhen Life Sciences Industry Association，简称：SLSIA），是2016年由北科生物、华大基因、融汇仁和、泰康人寿、达实智能和爱视集团等多家行业领军企业，以及深圳大学生命科学与海洋研究院、北京先进院、深圳北大医院、深圳市第一人民医院等高校和医院联合发起的，是全国首家生命科学行业社团组织。

深圳市生命科学行业协会的目标，就是在生命科学领域树立协会的形象、扩大协会的影响、争夺协会的话语权，成为“立足深圳、引领全国、走向全球”的权威社会组织，团结和带领协会成员抱团发展，共同分享生命科学行业的风口机会和企业发展红利，为促进中国大健康产业做贡献。

联系人：

韩聪

+86 13027956297

+852 6501 3956

KOBAYASHI DENKI 小林電機



~ 創新技術 不傷人體 ~ 222nm波長遠紫外光消毒儀

- ✓ 創新技術不傷人體皮膚及眼睛，而傳統紫外線過量會傷害人體。
- ✓ 不傷人體，實現人機共存，使用者可受全天候保護。
- ✓ 使用者可如常在222nm紫外線下活動，毋須像傳統紫外線必須關掉才可進入。

查詢電話：+852 2764-9028 / 技術支援：+852 6371-1490

電郵：sales@kobayashi-denki.com.hk / hardy1.kobayashi@gmail.com

 @kobayashi_denki_hk  小林電機 Kobayashi Denki HK



Tak Wah Mak 麦德华

**Director, Campbell Family Institute for Breast Cancer Research
Princess Margaret Cancer Centre, University of Toronto**

Tak W. Mak is internationally known for his pioneering work on the genetics and molecular biology of cancer and the immune system. His group was the first to clone the gene encoding the human T cell receptor, providing the basis for CAR-T and TCR-T treatments. His team also showed that CTLA4 negatively regulates T cell activation, paving the way for checkpoint inhibitor immunotherapy. Most recently, his team established that the brain communicates with the immune system via T and B cells producing acetylcholine.

In the biotech arena, Dr. Mak was the Vice President of Research at Amgen as well as co-founded several companies including Agios Pharmaceuticals and Treadwell Therapeutics. These companies specialize in developing first-in-class drugs delineating metabolic and immunological vulnerabilities in tumour cells that can be exploited as novel therapies. Two IDH inhibitors and one drug directed at PKR are now FDA-approved for AML treatment and anemia patients, respectively. At Treadwell, three first-in-class agents targeting aneuploidy and immunotherapy focused on advanced cancers are now in phase II clinical trials.

Dr. Mak has published 1000 peer-reviewed research papers, holds dozens of patents, won numerous scientific and medical awards and is a recipient of a dozen Honorary degrees in Europe, Asia and North America.

ROMEGA

挪威鱼籽油

NATURE'S FINEST  BEST ω -3 AVAILABLE

Arctic Bioscience公司介绍

欧洲上市医药公司（股票代码：ABS）Arctic Bioscience致力于鱼籽油创新医学药物研发和临床营养产品研究，传递挪威健康生活理念。ROMEGA是其旗下医学营养品牌，目前已开拓母婴健康、大脑健康、视觉健康等方面临床营养产品，满足人类全生命周期营养需求。

BIOHK AUDITORIUM | BIOHK 會堂

Immunotherapy, Neurology, Infectious Diseases

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Is CAR-T Therapy Finally Affordable?

10:00 - 11:00

Moderator: Ms. Diana Viola, PharmaBoardroom

Panelists:

Dr. Azucena Gonzalez, Hospital Clinic de Barcelona*

Dr. Lin Yang, PersonGen BioTherapeutics

Dr. Gina Jiang, HKIB

Dr. Stephen Liu, (ST PHI Therapeutics)*

Exploring The Marvels of The Brain

11:00 - 11:30

Keynote Speaker: Prof. Wise Young, Mononuclear Therapeutics Limited
Neurogenesis for Stroke, Spinal Cord Injury, and Cardiac Arrest

Chair: Dr. Charles Hu, Ryoden Medical Holdings Ltd.

11:30 - 11:45

Targeting Receptors for Brain Diseases

Prof. Wei Chen, Beijing Tiantan Hospital, Capital Medical University

11:45 - 12:00

How Does The Brain Regain Consciousness from Anaesthesia?

Prof. Xuejun Song, Southern University of Science and Technology

12:15 - 12:30

A Breakthrough in Implantable Photo-medicine

Dr. Charles Hu, Ryoden Medical Holdings Ltd.

12:30 - 12:45

脑机接口·让大脑连接未来

Mr. Lei Peng, NeuroXess

12:45 - 13:00

POINT: Breakthrough Therapeutics for Brain Disorders

Mr. Coach Wei, Neural Galaxy

13:00 - 13:15

基于脑机接口的神经调控技术及产业化

Mr. Peng Cao, Genlight*

13:15 - 14:00

Lunch Break

Battle with The Infectious Titans

14:20 - 14:50

Keynote Speaker: Prof. Pei-Jer Chen, National Taiwan University and Hospital
Hepatitis B Control: Illustrating the Impact of Collaboration

14:50 - 15:20

创新转化与新冠病毒的科学防治

Prof. Hongzhou Lu, Shenzhen Third People's Hospital

15:20 - 15:50

Diagnostic Stewardship: Strategies to Enhancing Antimicrobial Prescribing

Prof. Margaret Ip, The Chinese University of Hong Kong

15:50 - 16:20

Data science approaches to infectious disease surveillance and control

Dr. Qingpeng Zhang, The University of Hong Kong

16:20 - 16:50

Long COVID-19 symptoms in cohort and case-control studies: a systematic review

Dr. Dexing Zhang, The Chinese University of Hong Kong

Landscape Overview of mRNA Therapeutics

Dr. Bo Ying, Abogen Biosciences

16:50 - 17:00

基于脑机接口的神经调控技术及产业化

Dr. Jiasheng Song, Difference Biological Tech

*No biography or information was provided before September 01, 2023.

GENERATIVE AI

TO IMPROVE THE **QUALITY** AND **PRODUCTIVITY** OF PHARMACEUTICAL RESEARCH

31 PROGRAMS IN TOTAL

29 TARGETS COVERED

4 CLINICAL-STAGE PROGRAMS

BOOTH NO. 3D-B25

PHARMA.AI


FULLY-INTEGRATED END-TO-END
GENERATIVE AI AND ROBOTICS
DRUG DISCOVERY SYSTEM



Biology42




Chemistry42



Medicine42

THERAPEUTIC PROGRAMS AS OF AUGUST 2023



GET FULL
PRECLINICAL PACKAGE

ADJUST CLINICAL DEVELOPMENT
STRATEGY TO YOUR PIPELINE

GAIN ACCESS TO ALL PHARMA.AI PLATFORM
AI TOOLS TO INCREASE INTERNAL CAPABILITIES

USE INCLINICO TO OPTIMIZE
CLINICAL DEVELOPMENT



Insilico Medicine

INSILICO.COM





Diana Viola

**Chief Executive Officer
PharmaBoardroom**

Diana Viola is CEO and cofounder of PharmaBoardroom.com, a global platform for high-level dialogue between government authorities and regulators, C-level industry executives, financial investors and other key stakeholders, as well as Healthcare and Life Sciences Review, comprehensive digital reports covering various healthcare markets and industry thematic. In total, both platforms reach over 53,000 global industry stakeholders across the entire value chain from R&D, manufacturing, and marketing and sales, to supply chain distribution, logistics and other services. Over the past 15 years, Diana has been committed to driving global engagement on relevant industry topics, trends and debates, sharing best practices across international markets, and advocating for collaboration and innovation within the healthcare and life sciences industry.



Lin Yang 杨林

**Founder, Chairman and Chief Scientific Officer
PersonGen BioTherapeutics (Suzhou) Co., Ltd.**

Dr. Lin Yang, Founder/Chairman/Chief Scientific Officer of PersonGen BioTherapeutics (Suzhou) Co., Ltd.; Distinguished Professor of Soochow University. He was an adjunct professor at MD Anderson Cancer Research Center, and has won many honors, including the Highest Honor in the National Disruptive Technology Innovation Contest Finals of the Ministry of Science and Technology of PRC. Dr. Yang has published more than 100 peer reviewed articles, including Cancer Cell, Cancer Research, Clinical Cancer Research, etc., and has been leading PersonGen team to develop a number of breakthrough first-in-class CART drugs, including the world's first approved INDs of autologous CD7-CAR-T and B7-H3-CAR-T injections for T lymphocyte-derived malignancies and pediatric solid tumors, respectively. He also plays a critical role in building an internationally advanced industrialization base based on the fully automatic CART cell production process in China.



Gina Jiang 江宜蓁

**Managing Director
Hong Kong Institute of Biotechnology (HKIB)**

Dr. Gina Jiang has been the Managing Director of The Hong Kong Institute of Biotechnology (HKIB) and the affiliate of The Chinese University of Hong Kong (CUHK) since April 2020. She is leading the institute to establish one of Hong Kong's first Advanced Therapy Products GMP facilities and to upgrade the institute's well-known Traditional Chinese Medicine (TCM) GMP capacities.

A medical entrepreneur that sits at the intersection of medicine, design, and technology, Dr. Jiang is driven by patient-centered novel technology integration, and devotes her effort to its strategic planning and execution. Prior to joining CUHK, Dr. Jiang co-founded, built, and enjoyed running a number of medtech startups in Silicon Valley and Taiwan.

天坛生物是中国医药集团有限公司、
中国生物技术股份有限公司
旗下唯一**血液制品**专业公司

拥有6家血液制品公司 100多家单采血浆站

Owning 6 blood product manufacturers and
more than 100 plasmapheresis centers

公司致力于为社会提供**更多品种、更多数量
和更优质**的血液制品


Owning 6 blood product manufacturers and
more than 100 plasmapheresis centers

新产品介绍

New Products Introduction

注射用重组人凝血因子VIII

中国血液制品企业**首个**推出的重组人凝血因子VIII产品



努力成为**中国领先**，具有**国际影响力**，
受到社会尊重的血液制品公司

To be a Chinese leading blood product
company with international influences
and worldwide reputation


2023年入选国务院国资委

“创建世界一流专业领军示范企业”

Selected by SASAC as a “Building
World-Class, Specialized, Refined, and
Innovative Demonstration Enterprises” in 2023

蓉生静丙®10%

中国**首个**第四代静丙（层析法）产品浓度高达10%



☎ 电话: 010-65777816

✉ 邮箱: btbp@sinopharm.com

📍 地址: 北京市朝阳区双桥路乙2号院

☎ Telephone: 010-65777816

✉ Email: btbp@sinopharm.com

📍 Address: Yard B2, Shuangqiao Road, Chaoyang District, Beijing, China



Wise Young 杨咏威

**Chairman and Lab Director
Mononuclear Therapeutics Limited**

Dr. Wise Young, founding director of the W.M. Keck Center for Collaborative Neuroscience and a professor at Rutgers, The State University of New Jersey, is recognized as one of the world's outstanding neuroscientists. He obtained a bachelor of arts degree from Reed College, a doctorate from the University of Iowa and a medical degree from Stanford University. After a surgery internship at New York University and Bellevue Medical Center, he joined the neurosurgery department at NYU. In 1984, he became director of neurosurgery research. In 1997, as part of Rutgers' commitment to the future, Dr. Young was recruited to establish and direct a world-class center for collaborative neuroscience.

Dr. Young was part of the team that discovered and established high-dose methylprednisolone (MP) as the first effective therapy for spinal cord injuries. This 1990 work upended concepts that spinal cord injuries were permanent, refocused research, and opened new vistas of hope. This team also played a major role in Andy Blight's signal work on 4-aminopyridine (4-AP), which shows significant promise for increasing nerve conductivity.

Dr. Young developed the first standardized rat spinal cord injury model used worldwide for testing therapies, formed the first consortium funded by the National Institutes of Health (NIH) to test promising therapies, and helped establish several widely accepted clinical outcome measures in spinal cord injury research.

Dr. Young founded and served as editor-in-chief of the Journal of Neurotrauma. He organized the National and International Neurotrauma Societies as forums for scientists to share discoveries and collaborate on spinal cord injury and brain research. He serves or has served on advisory committees for the NIH, the National Academy of Sciences, and NICHD, and has served on advisory boards for many spinal cord injury organizations.

Well-known as a leader in spinal cord injury research, Dr. Young has appeared on "20/20" with Barbara Walters and Christopher Reeve, "48 Hours," "Today," "Eye-to-Eye," Fox News and CNN's news magazine with Jeff Greenfield. His work has been featured in a Life magazine special edition, USA Today, and innumerable other news, talk and print presentations throughout the world. His honors include: NIH Jacob Javits Neuroscience Award (1985-1992), Wakeman Award (1991), Tall Texan of the Year Award (1997), 'Cure' Award (1998), Trustees Award for Excellence in Research (2001), Asian American Achievement Award (2002), Douglass Medal for work with the advancement of young women in the sciences (2003), and Elizabeth M. Boggs Award for service to the disability community (2004). In August 2001, TIME Magazine named Dr. Young as 'America's Best' in the field of spinal cord injury research. In 2005 he was the first researcher elected to the Spinal Cord Injury Hall of Fame. Dr. Young was appointed to the Richard H. Schindell Chair in Neuroscience in 2006 by the Rutgers University Board of Governors.



Wei Chen 陈伟

Professor

**China National Clinical Research Center for Neurological Diseases
Capital Medical University**

Dr. Chen has led a comprehensive translational research team focusing on the molecular mechanism of G protein-coupled receptor regulation and the development of new drugs. He discovered novel mechanisms in the regulation of non-classical G protein-coupled receptors by β -arrestin and GRKs, including receptors such as Frizzled, Smoothened, and TGF β III. He established an image-based drug screening platform, aiming to discover new drugs for the treatment of brain and other diseases stemmed from his own discoveries. Thus far his research team has discovered 1) bioactive ingredients in FDA-approved glucocorticoid drugs and natural products promoting stem cell proliferation for regenerative medicine, 2) a new therapy for stroke, 3) effective inhibitors for the treatment of Hedgehog-dependent medulloblastoma, and 4) novel small molecules for the treatment of refractory epilepsy. He received the honor of "Scholar" from the V Foundation and the American Cancer Society. He has authored over 50 publications and 10 patents in the area of receptor biology and drug discovery.



Xuejun Song 宋學軍

Director

**SUSTech Center for Pain Medicine, Southern University of Science
and Technology (SUSTech)**

Xue-Jun Song, MD, PhD, is currently Professor of Neurobiology, Anesthesiology, and Oncology, Director of SUSTech Center for Pain Medicine, Southern University of Science and Technology (SUSTech), Shenzhen, and Executive Director of Center for Pain Medicine, Peking University Health Science Center, Beijing, China. Dr. Song received his MD from Xuzhou Medical University and PhD from the Institute of Neuroscience, Chinese Academy of Sciences. Dr. Song did his Postdoc at Yale University Medical School and then served as an assistant, associate and full professor and director in Parker University Research Institute, Dallas, Texas, for eighteen years. Dr. Song's research has been focusing on understanding the neural mechanisms of chronic pain after nerve injury, bone cancer, diabetes, and exploring molecular targets for treatment of neuropathic, cancer and diabetic pain. His research has resulted in several dozens of publications in the prestigious journals including Anesthesiology, Brain, Cancer Research, FASEB J, JCI, J Neurosci, Nat Neurosci, Pain, etc. patents for chronic pain treatment. Dr. Song also serves as president of CASP / China Chapter of IASP, vice chair of Chinese Physiological Society Pain Translational Research Subcommittee, standing member of committee of Chinese Pharmacological-Anesthetics Society, International Chinese Academy of Anesthesiology, etc. and board member/associate editor of PAIN Reports and chief editor for English of Chinese J Pain Medicine.



Hillgene
谱新生物

让细胞药物谱写生命新篇章
CELL THERAPY INNOVATION INSPIRED

聚焦細胞藥·一站式CDMO服務

A leading CDMO platform for cell-based therapeutics



Plasmid



mRNA



Lentivirus



CAR-T/TCR-T/
CAR-NK



Immune Cells



Stem Cells

- IIT服務
IIT Services
- 工藝優化及IND申報
Process optimization and IND application
- 註冊臨床及商業化生產
Registered Clinical and Commercial Manufacturing
- CQDMO服務模式
CQDMO Service Mode

8⁺

Direct/indirect successful
IND applications

2⁺

Registered clinical
preparation experience

20⁺

cooperated with more
than 20 hospitals

200⁺

GMP batches lentivirus
manufacturing

200⁺

prepared cells for clinical use

18000⁺

Cell Factory Area (m²)



Coach Wei

Co-founder and CEO
Neural Galaxy

Coach Wei is the Co-founder/CEO at NeuralGalaxy. Coach previously worked as the Chairman of Nexaweb Technologies, a Boston based company he founded in 2000 that pioneered Rich Internet Applications and enterprise web 2.0. He raised over \$20M in venture capital for Nexaweb, built a global team, grew the revenue from zero to multi-million dollar and achieved over 7,000 global deployments of the Nexaweb Platform. At Nexaweb, he served a variety of roles including CEO, VP Engineering, CTO and marketing from 2000 to 2008. Before Nexaweb, Coach designed software for managing storage networks at EMC Corporation.

Coach is a frequent speaker on technology, industry trends and startup ecosystems, and serves on advisory boards of several Boston-area startups. He has received awards for his work on Ajax, Rich Internet Application and Entrepreneurship, including the "Interactive Experience Award" in 2005 and "Boston Top 40 under 40" in 2007. Coach holds a master's degree from MIT, six patents and maintains a blog on startups, web 2.0 and entrepreneurship.



Phoenix Peng 彭雷

Founder and Chief Executive Officer
NeuroXess

A successful serial entrepreneur with ventures spanning across Local Services, SaaS, Data mining, CRM, SNS, and other various enterprise applications. Founder and CEO of Keruyun, which was acquired by Alibaba Group for nearly 1 billion CNY in 2019.

Co-founded NeuroXess in 2021 and is serving as its CEO. The company has raised nearly 100 million RMB since its establishment, led by Shanda and Sequoia Capital. In 2022, NeuroXess received hundreds of millions of RMB in Series A financing led by Zhongping Capital, which is the largest early-stage financing in this field in China.

Mr. Peng holds a M.S. degree from Hong Kong Polytechnic University and a B.S. degree from University of Science and Technology of China.



Pei-jer Chen 陳培哲

Professor

National Taiwan University and Hospital

Professor Chen was appointed Director of the Hepatitis Research Center at the National Taiwan University Hospital in Taipei in 2001-2003, and now the faculty for Graduate Institute of Clinical Medicine, National Taiwan University. He was the President of the Taiwan Association for Study of the Liver (TASL) from 2012 to 2013. He served as the President of Taiwan Society of Virology from 2016-2018.

Upon completing his doctorate, Chen returned to National Taiwan University as a postdoctoral researcher, later joining the faculty in 1987. He was elected a member of Academia Sinica in 2006, and into The World Academy of Sciences in 2011. Chen specializes in hepatitis research and helped treat patients during the 2003 SARS outbreak, and was invited to a SARS-related seminar hosted by the World Health Organization, but did not attend because he was unable to isolate sufficiently after treating SARS patients, per the regulations in force for that meeting. Chen was invited to the 2009 World Health Assembly as part of the Chinese Taipei delegation. During the COVID-19 pandemic in Taiwan, Chen served on the vaccine review committee until late May 2021.

His research interests cover on the molecular virology and immunology of hepatitis viruses, and the genetic and genomic study of hepatocellular carcinoma. Professor Chen's clinical research include the natural history of chronic viral hepatitis and hepatocellular carcinoma, and also explores and conducts new therapies and trials for both diseases. He has published over 630 articles in the areas of hepatitis and hepatocellular carcinoma.

He served in the Editorial Board of Gastroenterology between 2017-2019. He was a was a member of the editorial board of the journal Hepatology from 2001 to 2006, 2010-2011, and 2019-2021. In 2000, Professor Chen was awarded the International Research Scholar in Infectious Diseases by the Howard Hughes Medical Institute for a period of five years. He has been elected into Academia Sinica in year 2006, and become the TAWS member in year 2011.



Hongzhou Lu 卢洪洲

Director

The Third People's Hospital of Shenzhen

Dr. Hongzhou Lu is the President of Shenzhen Third People's Hospital. Dr. Lu received his M.D. and Ph.D. degrees from Shanghai Medical College of Fudan University in 1999. He is a leading HIV and influenza expert in China and has published over 70 refereed papers in international journals, including three original articles in New England Journal of Medicine as he was the physician who reported the first case of H7N9 avian influenza A virus infections in humans. He played an active role in clinical management, academic communications, and public education during the H7N9 avian influenza outbreak in China. Dr. Lu was also one of the first batch of Chinese public health experts who worked over 65 days in Sierra Leone to fight against Ebola. Dr. Lu currently serves on five editorial boards of international journals and several boards of major government and academic organizations in China. His awards include the Leading Figure in China's Combat with SARS and the Shanghai Science and Technology Progress Award.



Margaret Ip 葉碧瑤

Professor and Chairman, Department of Microbiology

The Chinese University of Hong Kong

Margaret Ip is Professor and Chairman at the Department of Microbiology, Faculty of Medicine, Chinese University of Hong Kong, and Honorary Consultant at the New Territories East Cluster of Hospitals of Hospital Authority. She is a clinical microbiologist with over 25 years' experience in research on the epidemiology and antimicrobial resistance of clinically important bacterial pathogens, inc. MRSA, Streptococcus pneumoniae, Streptococcus agalactiae (Group B Streptococcus) and other multidrug-resistant organisms. She has published over 290 international peer-reviewed papers. She serves as an Advisor and Member in a number of Scientific Committees on antimicrobial resistance and infection control and in Expert groups on GBS with WHO and FAO. She has supervised 20 fulltime completed PhD/MPhil students. She is an Examiner for the Hong Kong College of Pathologists and of the College of Physicians (in Infectious Diseases), and an external examiner for Universities locally and overseas in Malaysia, Australia and United Kingdom.



Dexing Zhang 張德杏

Research Assistant Professor

JCSPHPC, Faculty of Medicine

The Chinese University of Hong Kong (CUHK)

Prof. Zhang obtained her Bachelor of Medicine (Preventive Medicine) and Master of Medicine (Social Medicine and Health Service Management) from School of Public Health, Xiangya Medical College, Central South University, China. She obtained her PhD in Public Health in 2013 at CUHK and worked as a postdoctoral fellow in the school afterward. During her PhD study, she received an award to go to the University of Bristol, UK for a three-month research visit. In the last five years, as a co-investigator, Prof. Zhang received 9 research grants (a total of more than HK\$5 million) from GRF, HMRF, RFCID, HCPS, NSFC, CUHK Direct Grant and Knowledge Transfer Project Fund, and Department of Health. The projects cover a range of populations from children to adults with different methodologies including cross-sectional and cohort study, RCT, systematic review and qualitative study, within the field of primary health care and mental health.



Bo Ying 英博

Co-Founder and CEO
Abogen Biosciences

Dr. Bo Ying obtained his Bachelor's and Master's degrees in life sciences and neurobiology, respectively, from Fudan University. He went to the U.S. in 2006 to continue his study and obtained his PhD in pharmaceuticals from Northeastern University.

Before he returned to China in 2019, he worked at Boston's Moderna, Inc. as a senior scientist and a group leader in charge of building the company's drug formulation team for cancer immunotherapy, leading the team to develop several mRNA-based immunotherapeutic drugs. In addition, he was one of the founding members of TruCode Gene Repair, Inc., responsible for pharmaceuticals development, CMC, and GPM drug production. Dr. Ying is currently the CEO of Abogen, Inc.



Qingpeng Zhang 张清鹏

Associate Professor
Department of Pharmacology and Pharmacy and the Musketeers Foundation
Institute of Data Science, The University of Hong Kong

Dr. Zhang Qingpeng is an Associate Professor at the Department of Pharmacology and Pharmacy and the Musketeers Foundation Institute of Data Science, The University of Hong Kong. Dr. Zhang has been dedicated to interdisciplinary research in artificial intelligence and medicine. His research results have been published in top journals such as Nature Human Behaviour, Nature Communications, PNAS, JAMIA, MIS Quarterly, and have been widely reported by media including The Washington Post, The New York Times, The Guardian, Radio-Canada, Ming Pao. He received The President's Award and Outstanding Research Award from CityU, and the Andrew P. Sage Best Transaction Award from IEEE. His collaborative research with the Chinese Academy of Sciences has been recognized as the Outstanding Group in the National Science and Technology System against the COVID-19 Epidemic.



Jiasheng Song

Founder
Difference Biological Technology Co., Ltd.

Dr. Jiasheng Song is the Founder of Zhejiang Difference biological Technology Co., Ltd. He received his Ph.D. from Chinese Academy of Agricultural Sciences in 2010. He performed his postdoc research in UW-Madison (Yoshihiro Kawaoka lab), UPMC and Emory University during 2010-2016. Dr. Song is strong in molecular virology and the development of genetic engineering vaccines. Currently, there are two vaccine products that are in the process of industrialization. (1) A novel DIVA influenza vaccine; (2) A recombinant NDV vector Covid-19 vaccine. Over the past years, he deeply involved in several national and international key projects including Global Health Grant (Number OPPGH5383, Bill & Melinda Gates Foundation, "High-throughput analysis of avian influenza variants for pandemic potential") and the National Basic Research Program of China (973 Program).

Currently, Dr. Song takes charge of the project "Hangzhou Hi-Tech Zone 5050 Plan" (the title is Development and implementation of a novel DIVA influenza vaccine). 3 National invention patents have been licensed and 9 International patents have been applied.



Centre for
Immunology & Infection
免疫與感染研究中心

BOOTH NO. 3E-C27, 3E-C25

Centre for Immunology & Infection

*Using novel technology platforms for biomarker discovery and
the development of new vaccine and therapeutic strategies.*

- ✓ C2i is composed of an international team that leverages a highly multi-disciplinary expertise
- ✓ 1,000m² facilities including state-of-the-art laboratories, an advanced insectarium unique in Hong Kong, and a dedicated research clinic established for cohort recruitment
- ✓ Fostering innovation and evolving in the multidisciplinary environment offered by Science Park (HKSTP)
- ✓ The most advanced equipment and technologies supporting cutting-edge research to push the boundaries and drive groundbreaking discoveries

Healthy Human Global Project - Hong Kong



Novel Vaccine Platforms for Influenza



Mosquito-borne Viruses Epidemiology, Pathogenesis and Interventions



Novel Platform of Human Respiratory Tract



C2i is the fruit of a long-standing partnership of more than 20 years between the **LKS Faculty of Medicine of the University of Hong Kong** and the **Institut Pasteur**, two major institutions combining their expertise to establish this centre of excellence.

Our work is centered around four major research programs to face public health challenges and make Hong Kong a global center of excellence for precision medicine population strategies and innovative interventions targeting emerging infectious diseases.

C2iTech

SPIN OFF COMPANY



T +852 3910 3998 || info@c2i.hk || www.c2i.hk
Unit 1111-1113, 11/F, Building 17W, 17 Science Park West Avenue
Hong Kong Science Park, Shatin, New Territories, Hong Kong
香港新界沙田香港科學園科技大道西17號11樓1111-1113室

@centre2i
   
www.c2i.hk



INNOVATION GALLERIA | 創新廊

Commercialising Research

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Government Funding For Life Sciences

10:00 - 11:00

Mr. Alfred Tan, The University of Hong Kong
Dr. Rose Ching, Hong Kong Science & Technology Park*

Clinical Trials in Hong Kong

11:00 - 12:00

Moderator: Ms. Diana Viola, PharmaBoardroom (see biography on p.126)

Panelists:

Mr. Henry Yau, HK Clinical Trials Center
Dr. Karen Chu, Harvest Integrated Research Organisation
Dr. Danny Yeung, Gilead Sciences*

Searching For The Next Life Science Unicorn

12:00 - 13:00

Chair: Dr. Da Liu, CR-CP Life Science Fund (see biography on p.58)

Panelists:

Mr. Nigel Yip, Sirnaomics
Mr. Simon Hua, China Finances Strategies Investment Holdings Ltd
Mr. Martin Law, MiRXES Hong Kong Ltd

13:00 - 14:00

Lunch Break

From Lab to IPO (Sponsored by Jun He)

14:00 - 15:00

Moderator: Ms. Zhijin Zhang, Jun He

Panelists:

Ms. Lihua De, Jun He
Mr. Xudong Tao, Jun He

Biotech Capital Markets in HK and GBA

15:00 - 16:00

Chair: Mr. Vijay Karwal, AffaMed Therapeutics

Panelists:

Mr. Samuel Thong, Goldman Sachs
Mr. Andrew Siu Wan Ng, Private Equity at VMS Group
Mr. Sammi Wong, HKSTP Capital
Ms. Helen Chen, LEK Consulting
Dr. Dong Li, Hong Kong APX Capital

The Outlook for Emerging Biotech Companies

16:00 - 17:00

Chair: Mr. Yuyao Peng, China Renaissance Securities

Panelists:

Mr. Mikio Tanji, Defta Capital
Mr. Adrian Lam, Bioworld Ventures
Mr. Honggang Zuo, Genecast Biotechnology
Mr. Jielun Zhu, Fapon Group
Dr. Charles Hu, Cere Ventures
Viva HE, Managing Director, AZ-CICC Venture Investment Fund*

*No biography or information was provided before September 01, 2023.

Sponsored by

 JUNHE | 君合律师事务所

Unlock the Secrets to Your Better Health with Saliva



Innovative Saliva Test

- Innovative
- Painless
- Easy to Use
- Home-based
- Trend Monitoring
- AI-assisted Analysis

Know you Risk

Stress	Diabetes
Infection	Nutrition
Cardiac	Stroke

 info@enanohealth.com

 +852 2210-5022





Alfred Tan

Deputy Director

Technology Transfer Office, The University of Hong Kong

Ir. Dr. Alfred Tan is currently serving as the Deputy Director of the Technology Transfer Office at The University of Hong Kong (HKU). He is also the Deputy Managing Director and a Board member of Versitech Limited.

Before joining HKU, Ir Dr Tan spent over 13 years as the Head of the Knowledge Transfer Office (KTO) at Hong Kong Baptist University (HKBU). During his tenure, he played a key role in facilitating the successful commercialization of numerous technologies, resulting in hundreds of millions of dollars in revenue for the university. Ir Dr Tan was also a member of both the Council and Court of HKBU, and served as the Managing Director of HKBU R&D Licensing Limited.

Ir Dr Tan possesses extensive knowledge and expertise in knowledge management, technology transfer, and intellectual property law. He holds a Bachelor's Degree in Engineering (Computer Systems) with First Class Honors, a PhD in Electrical and Electronic Engineering, and a Master's Degree in IP Law.



Henry Yau

Managing Director

HKU Clinical Trials Centre

Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre's mainland China arm. Mr. Yau explains how the clinical trials landscape has evolved in Hong Kong over the past five years, especially in relation to the COVID-19 pandemic. He also covers some hot-button issues in global clinical research and how they pertain to Hong Kong, including cohort diversity, digitalisation, and convergence with medicine regulation and approvals.



Karen Chu

Founder and CEO

Harvest Integrated Research Organization (HiRO)

Karen is the founder and CEO of Harvest Integrated Research Organization (HiRO). It is a global clinical research organization (CRO) stemming from Asia-Pacific and specializes in cross-border clinical research development. Prior to her role at HiRO, Karen was previously a Partner of Fontus Capital. She continues her role as Venture Partner in Fontus Capital as a member of the Investment Committee in evaluating and making decisions on investment opportunities. Currently, Karen is a board member for three US/EU Biotech companies in clinical stages. In her previous roles, she was the Corporate Vice President for Clinical Research Services at Parexel International. Karen led Parexel's global clinical operations, which was responsible for the operational delivery of Phase I-III clinical trials. The team of operations was ~6000 employees across 50+ countries. In addition to her extensive experience with clinical trials globally, she possesses a unique understanding of cross-border strategy and management. Karen holds Bachelor of Science and Doctor of Pharmacy degrees from Rutgers, The State University of New Jersey, College of Pharmacy.



Nigel Yip

Chief Financial Officer
Sirnaomics

Mr. Wing Kei Yip has 12+ years of transaction experience in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Mr. Yip worked at Credit Suisse (Hong Kong) Ltd. from 2015 to 2018 and successively serving as an associate in the firm's Investment Banking division and a vice president in the Ultra High Net Worth Entrepreneur Coverage department. In his current role, he manages the overall fundraising process for Sirnaomics and communication with the banking and investor communities.



Simon Hua

Chairman
China Finance Strategies Investment Holdings Limited

Mr. Hua is the Chairman and CEO of CFS. He joined BOCOMI in 2008 and headed its direct investment and investment banking businesses. He is a member of Investment Committee of BOCOMI funds that he raised and managed. Total capital under his management was USD\$1.5B. Prior to BOCOMI, he was the Managing Director of Investment Banking at CLSA and the Executive Director in China-Euro Securities Limited, an investment bank joint venture by CLSA in China. During his term, CLSA was awarded the best investment bank for medium-size enterprises in Asia. Prior to CLSA, Mr. Hua was General Manager of Corporate Finance of Cazenove Asia, and worked at ICEA, and Bank of America

From 2006 onwards, through his own private equity fund, Shanghai Shengya Investment and BOCOMI's direct investment funds, Mr. Hua made many private equity investments in China, including Guangxi Nanning Water Co. Ltd, Viva Biotech Limited, GCL Silicon Technology Holdings Inc, Bright Smart Securities, Sanjiang Chemical, Boshiwa, Sino Polymer, Topsec Holdings Ltd and Wison, etc.

Mr. Hua advised many China and Hong Kong enterprises, including PetroChina, Sinopec, Chinalco, China Telecom, Lenovo, TCL, China Insurance, Phoenix TV and Ctrip, etc. for their initial listings and refinancings. He also led many financial advisory projects, including the acquisition of Cntorch by Weichai Power and asset restructuring of Guangdong Investment, etc. In the past 18 years, he has completed about 200 listing and project financing projects and about 50 financial advisory projects. The total transaction amount is more than USD \$100B. Mr. Hua holds an MBA from International University of Japan.



萊奧德創



LYO INNOVATION

Booth No. 3E-A14


CDMO and Consultation Service

加速生物藥抗腫瘤 藥創新藥上市時間
Accelerate Biopharmaceuticals, ADC, Innovative medicines to the market



提升穩定性 Enhance Stability

拋除冷鏈運輸 Eliminate Cold-chain Transportation

延長貨價期 Extend Shelf-Life and Values



Process Optimization, Controlled Crystallization



- 樣品檢測分析**


 1. 樣品熱性能分析
 2. 關鍵溫度檢測分析
 3. 凍乾顯微鏡, DSC分析
- 配方優化**

 1. 凍乾配方審查調整
 2. 使用冷凍保護劑及凍乾保護劑
- 工藝路徑驗證**

 1. 使用保守工藝
 2. 建立多個備選工藝
 3. 從中篩選進入優化與開發
- 工藝開發**

 1. 使用之前得到嘅最佳配方
 2. 之前得到嘅最佳工藝進一步優化, 接近邊界
- 工藝放大**

 1. 根據樣品性質及期望的生產規模, 將生產工藝調整到適合生產的參數
 2. 放大相關知識介紹



ATS
LIFE SCIENCES SCIENTIFIC PRODUCTS

Global 500 Pharma & FDA Equipment Partner



TEGENT GROUP



SMLH AP



SMLH HK

FREE SAMPLES
Register Now

Tegent Group

Tel: +852-3910 1500 Fax: +852-2758 3830 Email: tegent@tegent.com.hk

Address: Suite 3605, 36/F, AIA Kowloon Tower, Landmark East, No. 100 How Ming Road, Kwun Tong



Tegent
德祥
since 1992

Your Local Specialist



TEGENT GROUP
30 YEARS
KEEP CONTRIBUTING • SHIFT FUTURE



Lihua De 德立华

Partner

JunHe LLP

Ms. Lihua De is a partner of JunHe LLP and a registered foreign lawyer in Hong Kong. She obtained a Bachelor's degree in Economic Law from Peking University in 1984, and became a practicing lawyer in China by passing the Chinese Bar Exam in 1987. From 1984 to 1986, she worked at the Ministry of Petroleum Industry of the People's Republic of China, and then practiced law at the Great Wall Foreign Economic Law Firm, a subsidiary of the Ministry of Foreign Economic Relations and Trade, from 1986 to 1992. From 1992 to 1993, Ms. De worked as a visiting lawyer at a British law firm and a British barrister's chambers, respectively, and from 1993 to 2006, she practiced law at two Hong Kong law firms before joining JunHe LLP in June 2006. In her more than 30 years of legal practice, Ms. De has accumulated extensive experience in various fields such as direct investment, mergers and acquisitions, securities markets, and antitrust. She provides various consulting services on direct investment, mergers and acquisitions, antitrust, and subsequent operations in China for clients from mainland China, Hong Kong, and overseas. Ms. De is also deeply committed to the issuance of domestic and overseas companies in China and Hong Kong, with services covering industries such as large-scale manufacturing, telecommunications, real estate, transportation, natural resources, e-commerce, and finance.

As a lawyer for more than 30 years, Ms. De has the rationality, integrity, and profound legal knowledge of a legal professional. She has been active in the front line of providing services to clients for many years, personally participating in numerous major projects, and striving to influence and drive lawyers to devote themselves to providing high-quality and efficient legal services with a good leadership image and exemplary role. She has served as a permanent legal advisor for companies such as China Shipbuilding Capital, COSCO Shipping, China Reinsurance (Hong Kong), China Merchants Group, and Huaneng. Since 2016, Ms. De has been a member of the Legal Professional Committee of the Hong Kong Chinese Enterprises Association, always providing multi-dimensional and thoughtful solutions for clients, and has been highly praised and trusted by the industry and clients.

Ms. De has had many years of close cooperation and smooth communication with various legal institutions in Hong Kong and Beijing. She is good at making friends and listening to different voices, and has the ability to coalesce and resolve conflicts to solve problems. Under the leadership of Ms. De, her law firm has been named "PRC Firm, Hong Kong Office of the Year" by Asian Legal Business eight times in the past eight years, and its business level and service quality have been widely recognized and praised. Ms. De was also nominated for Best Managing Partner and Best Deal Maker at last year's Asian Legal Business. As one of the first group of Chinese lawyers to obtain a practicing license in mainland China, Ms. De has a large client base and circle of friends, especially in Beijing. During her more than ten years of work in Beijing, she participated in many large-scale projects for introducing foreign investment and negotiated many representative Sino-foreign joint venture projects on behalf of Chinese clients and foreign companies. In 1993, Ms. De was also one of the first group of Chinese lawyers to work in Hong Kong.

For more than 30 years, she has provided legal services for many state-owned enterprises, central enterprises, Hong Kong companies, and multinational companies in overseas, Hong Kong, and mainland China's listings, mergers and acquisitions, and investment activities. In terms of social positions, Ms. De currently serves as a member of the Beijing CPPCC, Vice President of the Peking University Hong Kong Alumni Association, a member of the Legal Professional Committee of the Hong Kong Chinese Enterprises Association, an executive director of the Hong Kong Beijing Community Association, and a director of the Hong Kong Beijing University Alumni Alliance.



Zhijin Zhang

Partner
Junhe LLP

Ms. Zhang joined JunHe in 2006, and she has worked in both our JunHe Shanghai office and Jun He New York office. She was relocated to JunHe Hong Kong office from New York in 2012 and has practiced in our Hong Kong office since then. Ms. Zhang specializes in offshore various fund formation and downstream investment transactions, out-bound investment and cross-border M&A transactions, asset management and wealth management companies' multi-faceted cross border investment, equity, debt or structured financing transactions. Ms. Zhang has represented many Chinese sponsors and institutional investors (including Ministry of Finance of the PRC) in their fund formation projects with various offshore fund structures. For outbound investment and international bidding acquisition projects, Ms. Zhang is well-versed in representing Chinese companies in their world-wide investments. She is not only profound and seasoned in Chinese culture but quite sophisticated with both HK and international business and trading rules and regulations. She has been fairly active and experienced in representing startups, entrepreneurs and pioneering VCs from the perspective of overall legal and business compliance in the field of new economy, new consumption, hardcore science, artificial intelligence and healthcare.



Xudong Tao 陶旭东

Partner
Junhe LLP

Mr. Tao joined JunHe in 2001 and is a senior partner of their capital market practice.

Mr. Tao focuses on initial public offering by Chinese companies in domestic and overseas capital markets and post-listing matters, including: (1) deal structuring; (2) pre-IPO transactions such as M&A, ESOP and PE financing; (3) IPO by Chinese companies in domestic and overseas markets; (4) post-listing securities compliance, employee equity incentive schemes; (5) restructuring, takeover, take-private or re-listing involving listed companies, etc.

In overseas capital market area, Mr. Tao's most recent deals include: (1) underwriter's PRC counsel to DPC Dash Ltd. in its HKEX listing in March 2023; (2) underwriter's PRC counsel to JF Wealth Holdings Ltd. in its HKEX listing in March, 2023; (3) underwriter's PRC counsel to AIM Vaccine Ltd. in its HKEX listing in 2022; (4) underwriter's PRC counsel to Microport Medbot Group in its HKEX listing in 2021; (5) underwriter's PRC counsel to Dingdong (Cayman) Limited in its NYSE listing in 2021; (6) underwriter's PRC counsel to New Horizon Bio in its HKEX listing in 2020; and (7) issuer's PRC counsel to Vivo Biotech in its HKEX listing in 2019.

In domestic capital market area, Mr. Tao is the issuer's counsel to the following in their Scitech Board listing: (1) Baili Pharm, 2023; (2) Transwarp, 2022; (3) Hanova Pharma, 2022; (4) Chengdu HitGen, 2020; (5) Zelgen Pharma, 2020, and (6) Shanghai Amologic, 2019. Mr. Tao also acts as the underwriter's counsel to BeiGene Ltd in its Sci-tech Board listing in 2021 and issuer's counsel to Ecovacs Robotics in its listing on Main Board of Shanghai Stock Exchange in 2018.

Mr. Tao has been ranked as a "Leading Lawyer" by IFLR and Asia Law since 2012, a Recommended Lawyer by Chambers (Band I, 2020) and a "Stand-out Lawyer" by Thomson Reuters in 2021.



精明知識產權策略 業務升級增值秘訣

免費知識產權諮詢服務



- ▶ 香港律師會的執業律師（顧問）提供一對一諮詢面談服務
- ▶ 協助香港中小企業加深對知識產權（IP）的認識，制訂有效的知識產權管理及商品化策略

諮詢範圍涵蓋：



IP註冊



IP管理



IP授權



IP盡職審查

立即申請：www.ip.gov.hk/ipcs



知識產權培訓課程

增加專業知識和技能，全面提升管理企業知識產權的能力

基本課程

- ▶ 知識產權基礎課程
- ▶ 內地的知識產權管理與保護
- ▶ 香港的知識產權註冊及申請程序
- ▶ 企業保護商業秘密的策略與方法
- ▶ 專利基礎課程
- ▶ 加密貨幣、非同質化代幣、元宇宙和知識產權



IP保護



IP註冊



IP管理



IP策略

進階課程

- ▶ 知識產權審核及盡職審查
- ▶ 專利商品化和技術轉移的管理及策略
- ▶ 知識產權管理人員實務工作坊

課程概覽及報名：www.ip.gov.hk/ipmtp



知識產權管理人員計劃

- ▶ 協助香港企業（特別是中小企業）建立知識產權方面的人力資源，把握知識產權貿易所帶來的機遇
- ▶ 提供內容深入的知識產權培訓課程，讓企業的知識產權管理人員更有系統地增加專業知識和技能
- ▶ 所有在香港註冊的企業均可免費參加

為何參加？



優先報讀培訓課程



尊享培訓優惠



獲發參加證書



掌握最新IP資訊

更多：

- ▶ 免費參加知識產權管理人員實務工作坊及獲贈實務指南
- ▶ 以特價參加「亞洲知識產權營商論壇」

費用全免 立即登記

www.ip.gov.hk/ipms



瀏覽www.ip.gov.hk
了解最新的知識產權貿易支援服務及資訊

查詢熱線：2961 6833



知識產權署



Vijay Karwal 偉績加

**Executive Director and Chief Financial Officer
AffaMed Therapeutics**

Vijay Karwal is an Executive Director and Chief Financial Officer of AffaMed Therapeutics, based in Hong Kong. He brings over 27 years of global financial management and advisory experience in the healthcare industry with extensive background in business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He is also an Operating Partner at leading Asian healthcare investor CBC Group and serves as an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, exchange listed and headquartered in Bangkok, Thailand.

Vijay joined AffaMed from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the international provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, as Head of Healthcare Banking in North America at ABN AMRO, and as a senior member of ABN AMRO Rothschild – the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector, gaining extensive global experience across postings in London, Chicago, New York, Singapore and Hong Kong.

A native of the Netherlands, Mr. Karwal was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charterholder.



Samuel Thong

**Chairman and Co-head
Healthcare Investment Banking, Asia Ex-Japan**

Sam is chairman and co-head of Healthcare Investment Banking in Asia Ex-Japan. Sam joined Goldman Sachs in 2019 as a managing director. Previously, he was a senior banker at Morgan Stanley for 12 years in Hong Kong, covering the Asian healthcare sector. Prior to that, Sam covered US healthcare companies at Merrill Lynch in New York for 11 years. He earned a BA in Philosophy, a Doctor of Medicine degree and an MBA, all from the University of Chicago.



Sammi Wong

**Founding Member and Leader
HKSTP Ventures**

Sammi is an experienced venture capitalist and serves as a proactive board member to advise the investees in corporate strategy, international business development, governance and finance. As an appointed mentor of Hong Kong Life Science Society, he enjoys mentoring students regarding entrepreneurship in the areas of biomedical and healthcare sectors. Besides, Sammi is a guest lecturer at the University of Hong Kong and Awaji Youth Federation (Japan), coaching and teaching students in new venture creation and venture capital investing.

Sammi is the Founding Member and Head of the Hong Kong-based HKSTP Ventures, the venture capital arm of Hong Kong Science and Technology Parks Corporation. He oversees all the transaction executions, portfolio strategy and strategic partnership development since the inception of HKSTP Ventures in September 2015. The AUM of HKSTP Ventures has grown by 12 times throughout Sammi's five-year tenure. The investment portfolios under HKSTP Ventures are deep-tech focused, including Artificial Intelligence, autonomous driving, biomedical technology, robotics and semiconductor, and material science. Half of the investment portfolios are originated outside Hong Kong with investees located in Silicon Valley, Canada, China, Taiwan and the UK. Notable portfolio companies: ACT Genomics, AutoX, Fano Labs, Huue (UC Berkeley spin-off), Precision Robotics (Imperial College London spin-off), LuxCreo and Zeek etc.

Prior to joining HKSTPC, Sammi led the Greater China Distressed Investment team at Credit Agricole Corporate and Investment Bank. Besides, he obtained solid corporate finance exposure from his previous investment banking experience at ABN AMRO and BNP Paribas. Sammi has over 10 years of direct investment experience across industrials, real estate and various technology sectors in Greater China, Southeast Asia, Silicon Valley and the UK. He is a graduate of Saïd Business School, Oxford University with distinction and obtained CFA Charterholder qualification.



Helen Chen

**Global Sector Co-Head for Healthcare
Greater China Managing Partner
L.E.K. Consulting**

Helen Chen is Global Sector Co-Head for Healthcare and a Greater China Managing Partner of L.E.K. Consulting based in Shanghai. Helen was a member of L.E.K.'s Global Leadership Team from 2012 to 2016. She is also a Director of the firm's Asia-Pacific Life Sciences Centre of Excellence. Helen was named one of Consulting magazine's Global Leaders in Consulting in 2019.

Helen has over 30 years of consulting and industry experience in the U.S. and Asia markets and has lived in China since 2000. She helps companies expand their presence in China and Asia, and leverages Asia's innovation to improve their global businesses. For companies anchored in China, Helen advises on their drive to innovation and globalization. Helen is a frequent speaker and author on the opportunities and issues in China's healthcare and life sciences sectors. Her expert commentary has appeared in Bloomberg, Financial Times, The Wall Street Journal, Forbes Asia and the South China Morning Post, and in several industry publications, including BioCentury, In Vivo, Script and BioWorld.

Prior to joining L.E.K., Helen held senior management roles at several technology companies in the U.S. and China. She was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now Abbvie). Helen has an honors B.A. degree in Applied Mathematics from Harvard University.

Within Private Equity,
our sector focus and expertise span:

Healthcare

**Technology
&
Consumer**

A Trusted Alternatives Specialist

VMS Group was founded in 2006, and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong.

Apart from managing over US\$4 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, the Group has also seeded or accelerated other asset managers through strategic partnerships across Venture Capital and Hedge Fund strategies with another US\$6 billion under management.

10.3+ USD
billion

VMS Ecosystem
AUM[^]*

4.3+ USD
billion

AUM*

~400

Ecosystem
investments

80+

Professionals

[^] Comprising AUM from VMS Group, and its strategic partners.

* As of 30 April 2023.

Scan QR Code to follow our social media accounts

VMS Group Hong Kong | Beijing | Singapore

+852 2996 2100 | IR@vmsig.com | www.vmsam.com

LinkedIn



WeChat





***Li Dong* 董利**

Partner
Hong Kong APX Capital

Hong Kong APX Capital Partner Ph.D from Heidelberg University, Germany and Post Doc in King's College London. Worked as chief medical investment officer in Shenzhen Investment Holdings Co. Ltd and JinDong Capital. She has 20 years of experience of the healthcare industry and extensive networks and partnerships with medical companies in the Great Bay Area.



Yuyao Peng

Head
Hong Kong Healthcare Investment Banking, China Renaissance Securities

Yuyao Peng has worked in investment banking for several prominent companies. Yuyao started their career at Citi in 2012 as an Investment Banking Analyst and later became an Investment Banking Associate. In 2016, they joined Goldman Sachs as an Investment Banking Associate before being promoted to Investment Banking Executive Director in 2019. In 2020, they took on the role of Head of Hong Kong Healthcare Investment Banking at China Renaissance Huaxing Capital. Yuyao Peng obtained a Bachelor of Arts degree in Economics from Tsinghua University, where they attended from 2008 to 2012.



Mikio Tanji

Board Director
DEFTA Capital

After graduating from the University of Tokyo Faculty of Law in 1977, he gained various experiences as a banker at Long-Term Credit Bank of Japan, including overseas postings. After joining the firm, he led the launch of Qualipse, Osaka University's first venture, and later successfully completed an investment from an operating company. He was involved in the initial fundraising for the fund for which we are currently the GP, and ultimately closed the fund with an investment of USD 62 million. He is currently the general manager and investment steering committee member of the fund, where he presides over the investment steering committee, reviews investments, and serves as a director and auditor of several portfolio companies in the US and Japan.


He also serves as a director and auditor for several of the fund's portfolio companies in Japan and the U.S. He is a JD, and his experience as a business manager allows him to provide management guidance and formulate business strategies for venture companies through the board of directors.



Honggang Zuo

Chief Financial Officer
Genecast Biotech

Dr. Honggang Zuo previously served as a member of the Board from September 2017 to February 2018. Mr. Zuo was an executive director of Asian Special Situations Group of Goldman Sachs. Prior to that, he worked as an investment executive of Intermediate Capital Group in China, vice president of GE Capital in the United States, and director of MasterCard in the United States. In his earlier career, Mr. Zuo worked for PricewaterhouseCoopers in China. Mr. Zuo received his bachelor's degree in international business from Shanghai Jiao Tong University in 1998 and his master's degree in business administration from MIT Sloan School of Management in 2004.



依诺生物是一家拥有全球领先 mRNA 技术和 mRNA 领域全要素研发平台的生物科技公司。公司拥有 mRNA 药物和核心原辅料 GMP 级生产线，并成功构建 mRNA 药物集成产品开发体系，专家服务团队具备 mRNA 药物成功开发经验，可根据用户需求高效持续地提供 mRNA 研究整体解决方案。

ENO BIO is the world leading Biotech company engaged in mRNA technology and mRNA research and development in comprehensive platform. The company is equipped with GMP grade production line for mRNA drugs and core raw materials and excipients, and have successfully constructed mRNA development system. The expert team has deep expertise in developing mRNA drugs and providing integrated solutions for mRNA research with quality and efficiency.



Adrian Lam

**Managing Partner
Bioworld Ventures**

Mr. Lam is an accomplished equity portfolio manager and investor-operator in the healthcare sector, specializing in medtech, biotech and life science tools space. With an in-depth foundation in financial markets and engineering, he incorporates scientific knowledge, fundamental research, analytical insight and risk management into portfolio management and corporate development geared at generating risk-adjusted returns and alpha for investors. He has ten years of equity research experience in public and private markets and seven years of experience in developing FDA-approved medical devices, leading R&D teams and scaling healthcare ventures. He has successfully delivered unique global and interdisciplinary insights to both investors and operators.



Jielun Zhu

**Chief Financial Officer. and Chief Investment Officer
Fapon Group**

Jielun Zhu is an expert in finance and investment in the life science and healthcare industry with over 16 years of professional experience in investment banking and strategy consulting. As the CFO & CIO of FAPON, Jielun ZHU is in charge of financial management, capital market planning and execution, M&A, corporate venture investing and incubation at FAPON. He was the Managing Director and Head of Healthcare Investment Banking for Asia at Jefferies and formerly held various senior positions at UBS and Deutsche Bank. Before joining FAPON, Jielun ZHU served as the CFO of I-MAB Biopharma and supported the company in achieving numerous significant business and capital milestones.



Charles Hu 胡正忠

**Founding Partner
Cere Ventures Ltd**

Charles is a translational biomedical engineer with a strong background in business development. He co-founded Incando Therapeutics and heads Ryoden Medical where he oversees healthcare venture investments. He also advises angels, universities, and startups. He most recently established Cere Ventures — a syndicated group targeting and grooming brain- and ageing-related developments for and into the GHKM Greater Bay Area.

TECHNOLOGY HALL | 科技廳

Hot Trends in Biotechnology

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Artificial Intelligence in Healthcare	
10:00 - 11:15	<p>An Introduction of CP AI Biotech Works in Food, Health and Sustainability Mr. John Jiang, CP Group Future opportunities at the intersection of modelling, AI, supercomputing and clinical trials. Dr. Christopher Morten, ELEM Biotech How AI is Transforming Drug Discovery & Aging Research Dr. Frank Pun, Insilico Medicine Dr. Dimitris Samaras, Stony Brook University Patient care through AI-powered predictive solutions Dr. Echo Si Chen, Luca Healthcare</p>
Advances in Medical Biotechnology	
11:15- 13:00	<p>Symposiums:</p> <p>中国无创肠癌筛查的现状思考 Dr. Hongzhi Zou, Creative Biosciences BioRadar: The complete disease surveillance system starting with Pneumonia Dr. Jiangshan Zhan Haikang Life Cor. Development of SERS-based CRISPR/CAS9 sensor for the comprehensive detection of cancer-associated cfDNA utilizing transcription mediated production of malachite green aptamer Dr. Taejoon Kang, Korea Advanced Institute of Science and Technology Breakthroughs in technologies for mRNA therapies and some considerations on mRNA industry (mRNA疗法全链条技术突破与行业生态思考) Dr. Zhaoyu Hu, Rhegen Bio Breakthrough the impossible- leveraging liver regeneration to fight cirrhosis Dr. Kathy He, Cargene Biopharma 核酸疫苗/药物连续生产工艺实现及法规要求 Dr. Tao Kang, Medium Biomedicine (Suzhou) Co. Ltd Dr. Jinhai Shi Bing Biotech* Dr. Cole Zheng, Vector Builder*</p>
13:00 - 14:00	Lunch Break
Inflammatory Disease and Medicine	
14:00 - 15:30	<p>The JAK-STAT Pathway to Th-GM and Clinical Applications Chair: Prof. XinYuan Fu, West China Hospital. GenEros BioPharma</p> <p>Panelists:</p> <p>Dual Targeting Of Innate And Adaptive Immune Checkpoints With A Pd L1/Sirpalph Bispecific Macrophage Engager (Bime) For The Treatment Of Solid Tumors Dr. Hongtao Lu, Elpiscience Biopharma Generative AI Empowered Drug Discovery for Inflammatory Bowel Disease (IBD) Dr. Xiao Ding, Insilico Medicine Dual Action Tumor Immune Agonists from Tyligand Bioscience Dr. Tony Zhang, Tyligand Bioscience</p>
The Precision Medicine Era	
15:30 - 16:00	<p>Keynote Speaker: Prof. Allen Chen, Center for Novostics, The Chinese University of Hong Kong Cancer screening by circulating DNA analysis</p>
16:00- 17:00	<p>Chair: Dr. Desmond Hau, Pangenia Moderator: Dr. Jay Dong, UltraDx</p> <p>Panelists:</p> <p>Multi-cancer early detection via protein tumor markers and artificial intelligence Dr. Mao Mao SeekIn Inc. CARDIYON – A Novel Biotech Solution to Reduce the Risk of Cardiovascular Diseases Dr. Vince Gao Govita Tech Ltd Prof. Allen Chen</p>

*No biography or information was provided before September 01, 2023.



John Yue Jun Jiang

Chief Technical Officer
Charoen Pokphand Group

Dr Jiang had been leading digital transformation in CP Group, responsible for group cybersecurity, data privacy, cloud strategy, blockchain and AI. Since 2019, transitioning to Group CTO, supporting the CP Group CEO vision of best in class of applied technologies (in retail, healthcare, food as medicine, multiomics, microbiome, longevity, cancer vaccine, zero waste, carbon neutral, cleantech, alternative protein-materials-energy, green/torquoise hydrogen, battery, chip, satellite, quantum computing, biotech, nanotech, metaverse, web 3, generative AI, etc), tech leadership and centers of excellences.

President of iFree Group - a HK based unicorn conglomerate of real estate, restaurants, travel and smart city/retail digital technology group, spanning across Asia and Australia. Founding Board of blockchain based AI medical start up EVER (a rising unicorn) with millions of patient data and hundreds of hospitals for preventive health and drug discovery, 10s thousands of clinics for global medical tourism.



Christopher Morton

CEO
ELEM Biotech S.L

Specialized in emerging technology ventures and markets, Chris worked across mechanical industries (aero, auto, energy) before turning to health tech 4 years ago. With ELEM, Chris and his Co-Founder have taken up the challenge to deliver the most powerful and safe environment for medical trials by simulating human physiology on supercomputers. Prior to ELEM, Chris held executive roles at Atos and Sogeti HighTech (CapGemini), set up Altair France, founded and led Samtech UK until its acquisition by LMS, now Siemens. Chris has an international background, read Aeronautical Engineering at Imperial College and Business Studies at Hult IBS.



Frank Pun

HeadHong Kong Office
Insilico Medicine

Dr. Frank Pun is the Head of the Hong Kong Office at Insilico Medicine, where he leads a team of application scientists focused on the AI-driven biological target discovery platform, PandaOmics. His primary objective is to provide cutting-edge AI technology to scientists, medical professionals, biotechnology firms, and pharmaceutical companies worldwide, enabling them to identify actionable therapeutic targets and expedite the process of drug discovery and development. Frank received his Ph.D. in biochemistry from the Hong Kong University of Science and Technology in 2010. Following his graduation, he served as a visiting scholar, leading a team dedicated to studying human CNS diseases and cancer for several years. In 2019, he also obtained an MBA from Rutgers Business School in the United States. Throughout his career, Frank has made significant contributions to target discovery, publishing numerous impactful papers in the field. He is recognized as a key opinion leader in his respective domain.



Dimitris Samaras

**SUNY Empire Innovation Professor
Stony Brook University**

Dimitris Samaras earned his Ph.D. in Computer Science from University of Pennsylvania in 2001; M.S. in Computer Science from Northeastern University in 1994, and Diploma in Computer Engineering and Informatics from University of Patras, Greece in 1992. Dimitris Samaras's research up to now has focused on explaining visual data for Computer Vision, Computer Graphics and Medical Image Analysis, through the appropriate physical and statistical models. A central interest is in modeling the interaction of 3D shape and illumination, (a major source of variability in images) for applications such as shape and motion estimation, object recognition and augmented reality. His general interest in human modeling has led to exciting collaborations with psychologists who collect visual data about human behavior through multiple modalities such as eye-trackers and fMRI brain imaging.



Echo Chen

**CEO
LUCA Healthcare**

Dr. Chen received her PhD from the University of Cambridge with a major in biotechnology. During her time at Cambridge, she was involved in the development of biosensors and participated in the development of IVD technologies for AIDS, hepatitis B, and hepatitis C. She also participated in global support programs sponsored by the WHO and the Global Fund to help African governments fight infectious diseases. Currently, she serves as the CEO of LUCA Healthcare. With a mission to provide more affordable and accessible healthcare, LUCA Healthcare works with partners to build digital health solutions that diagnose, predict and manage patients for a healthier world.



Hongzhi Zou

**Founder
Creative Biosciences (Guangzhou) Co., Ltd**

Dr. Zou Hongzhi is the primary inventor of noninvasive sDNA test for early detection of colorectal cancer in the world. He is a National Major Talents Project expert.

Dr. Zou has tremendous expertise in research and development of molecular diagnostic technology in cancer detection and its related products. He was once the Director of R&D department at Exact Sciences Corporation where he developed Cologuard® which was cleared by FDA in 2014.

In 2015, Dr. Zou founded Creative Biosciences (Guangzhou) Co., Ltd and developed Colosafe® which is noninvasive sDNA test kit for colorectal cancer. Colosafe® is the first NMPA approved sDNA test kit receiving approval on Nov 20 2018, in China. In 2019, Dr. Zou received First Prize of Science and Technology Progress of Guangdong Province. In 2020, Dr. Zou was honored with Second Prize of China Medical Science and Technology Award. In 2021, Dr. Zou won First Prize of Science and Technology Progress by Ministry of Education.



Jiangshan Zhan

Council Member, CSO
Hai Kang Life Corporation Limited

Jiangshan Zhan, graduated from the School of Basic Medical Sciences of Peking University in 2017, and was awarded the honorary title of Outstanding Graduate of Beijing and Outstanding Graduate of Peking University. He received his Ph.D. degree in Neuroimmunology from the University of Munich, Germany, in 2021, and was awarded the Summa Cum Laude Score, and was selected for the introduction project of the Postdoctoral International Exchange Program in 2022, and is now working in the Postdoctoral Workstation of the Department of Medical Sciences of Peking University. Jiangshan Zhan is now working in the Postdoctoral Station of Peking University Medical School, mainly focusing on the research of oligodendrocytes in animal models of multiple sclerosis and the pathological features of clinical diseases. He has published 21 SCI articles, of which 11 are first author/corresponding author, and has co-authored 3 books.



Kathy He 何奇志

CEO
Lerna Biopharma Pte

Kathy He is the Chief Executive Officer of Lerna Biopharma Pte, an innovative biotech leveraging novel biology insights and proprietary siRNA platform to develop highly targeted and potent nucleic acid therapeutics for liver diseases. Ms. He has over 20 years of R&D and commercial experience from global pharma companies such as Abbott, Merck and Takeda, notably in building differentiated product portfolios, developing strategic opportunities, and successfully bringing innovative therapeutics to market.

Prior to joining Lerna, Ms. He was the Chief Business Officer (CBO) and General Manager at Kira Pharmaceuticals, where she led the closing of its \$60M Series B+ round of financing and built an operation in China to support Kira's global expansion. Before Kira, she was the CBO and Head of Corporate Development at Abbisko Therapeutics (HKEx stock code: 02256), where she led the raise of over \$100M and closed a series of cross-border strategic partnerships. In addition to her extensive operating experience, Kathy also worked as a Venture Partner and Managing Director at top tier investment firms in China.

Kathy received a BS degree in biology from Wuhan University, a MS in molecular biology from University of Illinois at Urbana-Champaign, and MBA from Kellogg School of Management at Northwestern University. She is currently a board member of Diagnostic Photonics, an innovative medical device company, a former trustee of Illinois Mathematics and Science Academy, and a past board member of the BayHelix Group, a non-profit professional organization for business leaders in life sciences and healthcare industries.



香港檢測和認證局
The Hong Kong Council for
Testing and Certification
www.hkctc.gov.hk



高度專業誠信
High Professional Integrity

完善的知識產權保障
Good Intellectual Property Protection

卓越技術水平
High Technical Competence

敏銳的市場觸覺
Quick Response to Market Needs

健全的認可制度，廣獲國際承認
Robust Accreditation System
Being Highly Regarded Internationally

作為自由港、擁有先進的物流支援
A Free Port with Excellent Logistics Support



使用獲香港認可處認可的機構所提供的檢測認證服務，可提高顧客對你的產品和服務的信心。

Using testing, certification and inspection services provided by Hong Kong Accreditation Service's accredited organisations could enhance customers' confidence in your products and services.



想找合適的獲認可機構，請瀏覽香港認可處網站：
To find a suitable accredited organisation, please visit the
website of Hong Kong Accreditation Service:

www.hkas.gov.hk





Taejoon Kang

**Principal Researcher, Bionanotechnology Research Center
Korea Advanced Institute of Science and Technology**

Taejoon Kang is an academic researcher from Korea Research Institute of Bioscience and Biotechnology. The author has contributed to research in topic(s): Medicine & Nanowire. The author has an hindex of 26, co-authored 95 publication(s) receiving 2445 citation(s). Previous affiliations of Taejoon Kang include Gwangju Institute of Science and Technology & Yonsei University.



Zhaoyu Hu 胡昭宇

**Vice President
Rhegen Bio**

Dr. Zhaoyu HU, Vice President of Rhegen Bio, an expert in the fields of chemical biology and biomedicine, who has rich experience and achievements in research fields such as mRNA vaccines and drugs, glycoconjugated vaccine and drugs, antiviral drugs, nucleoside modifications, targeted delivery and etc. He has promoted the development and clinical transformation of multiple innovative drugs and vaccines.



Tao Kang 康涛

**Vice President
Medium Biomedicine (Suzhou) Co., Ltd.**

Dr Kang, vice president of The Medium Biomedicine (Suzhou) Co., Ltd., Ph.D. graduated from Wuhan Institute of Virology, Chinese Academy of Sciences, Master's degree from University of Texas Health Science Center at San Antonio. He formerly served as a Visiting researcher at the University of Texas, Guest professor of Southern Medical University at Guangzhou, Director of translational development at Ractigen Therapeutics Co., Ltd., Director of technology and strategic development of Jiangsu Yaohai Biopharmaceutical Co., Ltd., Director of R&D of Guangzhou Recomgen Biotech Co., Ltd. More than 10 years of experience in biopharmaceutical development, registration and R&D management.



***Xinyuan Fu* 傅新元**

Chair Professor, West China Hospital, Chengdu
Founder and CSO, GenEros BioPharma, Hangzhou, China

Xin-Yuan Fu received his PhD in molecular biology at Columbia University in 1988 (Mentor: James Manley); postdoctoral training in Rockefeller University with James Darnell (1988-1991). Dr Fu was an Assistant Professor in Mt Sinai School of Medicine NY (1992-1994); an Associate Professor at Yale University (1994-2003), a Full Professor at Indiana University (2004-2015). Prof. Fu was the founding director of Tsinghua Institute of Genome Research of Tsinghua University, China (2000-2006) and the Head of Department of Biochemistry of National University of Singapore (2008-2011), Principle scientist and Professor, Cancer Science Institute of Singapore (2008-2018). Recently Professor Fu is taking academic positions in China, and developing therapeutics against inflammatory diseases. Dr Fu and his colleagues discovered the STAT gene family and the JAK-STAT signaling Pathway (Fu and Darnell et al, PNAS 89:7840-7843, 1992; Fu, Cell, 70:323-335, 1992). He has made a number of seminal discoveries in molecular mechanisms of mammalian development, immunity and diseases in the past 30 years. Particularly, in the past 23 years since Dr Fu's original discovery, there are about 40,000 publications on the JAK-STAT pathway, and over five FDA approved drugs against the JAK-STAT. Recently, Fu laboratory is focusing on STAT's role in regulation of inflammation, development and cancer. GenEros BioPharma is a cutting-edge drug discovery company founded by Dr Xin-Yuan Fu in 2015. GenEros pipelines focus on precision of medicine across inflammatory diseases and cancer.



***Hongtao Lu* 卢宏韬**

Co-founder and Chief Scientific Officer
Elpiscience Biopharma

Dr. Hongtao Lu is co-founder and Chief Scientific Officer of Elpiscience Biopharma, a biotech company focusing on innovative medicine for immuno-oncology. Trained as an immunologist and as an industry veteran for more than 20 years, he has extensive drug discovery experience across several therapeutic areas (autoimmune diseases, oncology and neuroscience) utilizing different therapeutic modalities (small-molecule and biologicals). Prior to Elpiscience, he had spent four years with Zai Lab, a NASDAQ-listed company, as co-founder and executive vice president for Scientific Research. Before Zai Lab, he was with GlaxoSmithKline as the founding head of Neuroimmunology Discovery Performance Unit (NI-DPU), where he led about 70 biologists and chemists focusing on drug discovery in neuroinflammatory diseases and neurodegenerative diseases. Dr. Lu spent his early career with Berlex Biosciences and Bayer Schering Pharma, where he conducted target identification and validation in autoimmune inflammatory diseases and oncology. Dr. Lu holds a Ph.D. in Regulatory Biology and conducted his graduate research at the Cleveland Clinic Foundation followed by post-doctoral fellowship at Yale University School of Medicine under the guidance of Dr. Richard Flavell.



Xiao Ding

**Senior Director, Head Of Chemistry
Insillico Medicine**

Xiao Ding has extensive work experience in the pharmaceutical industry. They currently hold the position of Senior Director and Head of Chemistry at Insillico Medicine since May 2021. Prior to this, they worked at Luo Shi Pharmaceutical from November 2020 to April 2021, where they served as the Scientific Lead in the Roche Accelerator program and as a Senior Scientist. Before that, Xiao Ding was employed at GSK, where they worked as a Scientist in the ND DPU, R&D China division from October 2012 to October 2017. They also had an internship at GSK from April 2011 to April 2012, where they worked as an Intern in the AB DPU at the UP site. Xiao Ding pursued their education in the field of chemistry with a focus on medicinal and organic chemistry. Xiao completed their Bachelor's degree in Organic Chemistry from Anhui University, where they studied from 2002 to 2006. After that, they furthered their studies at Shanghai Institute of Materia Medica, where they obtained a PhD in Medicinal Chemistry, graduating in 2011.



Tony Zhang 张彦涛

**Co-founder and CEO
Tyligand Bioscience**

Tony Zhang is the cofounder and CEO of Tyligand Bioscience, a clinical stage biotech focusing on the discovery and development of cancer therapeutics to address drug resistance in tumors like NSCLC and TNBC. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload development. Tony has a BS degree in chemistry from Shandong University and a PhD degree from Purdue University. Prior to founding Tyligand, he has served at Eli Lilly for 25 years with escalating responsibilities, including Senior Research Fellow of Small Molecular Design and Development, founding Managing Director of Eli Lilly China R&D; and Vice President of Lilly Global External R&D, Asia. Tony has led multi-disciplined teams in drug discovery and development across several therapeutic areas, and has published more than 60 articles and monographs in the fields of synthetic, medicinal and process chemistry, and pharmaceutical product design. He is the inventor for 30 patents and many commercial manufacturing processes. He has been recognized as a CGP fellow, a Purdue Distinguished Alumnus, and Eli Lilly's Chairman's Ovation Awardee. He has also served as the Chairman of BayHelix 2010-2011.



Desmond Hau

**Founder and CEO
Bio-Gene Technology Limited**

Dr. Desmond Hau is the founder and CEO of Bio-Gene Technology Limited, a leading distributor of laboratory instruments, reagents, and consumables in Hong Kong, Macao, and mainland China. With a background in biochemistry and a passion for shaping his own journey, he established Bio-Gene in 1993. Over the past 30 years, the company has evolved to become an authorized distributor for renowned manufacturers in the fields of analytical sciences, clinical diagnostics, food and pharmaceutical safety, and life sciences research. Desmond has successfully expanded the business into new areas, including laboratory design and setup services. With a strong focus on customer satisfaction and providing comprehensive support, he envisions further growth in the medical devices and pharmaceutical sectors. Desmond is also part of the Pangenia Group, where collaboration and synergy among the group's companies drive innovation and expansion in the healthcare industry.



展位号 Booth No.
3C-E2

自主全產業鏈基因工廠

業務涵蓋合成基因組學產品及服務、生命科學原料及設備、生物製造CXO三大方向

Beijing Tsingke Biotech Co., Ltd. is a world leading gene manufacturer, equipped with state-of-the-art R&D facilities for synthetic instruments, chemical and molecular biology reagents. Tsingke's integrated production platforms enable us to deliver cutting edge synthetic genomics products and services, life science research equipment and raw materials.



Tel: 400-668-3730 Web: www.tsingke.com E-mail: market@tsingke.com.cn
Add: Building 3, Unit W, No. 105 Jinghai 3rd Road, Beijing E-Town 100176, China.



Allen Chan 陳君賜

Professor, Department of Chemical Pathology 化学病理学教授
The Chinese University of Hong Kong 香港中文大学

Professor Chan is currently appointed as Professor of Chemical Pathology of the Chinese University of Hong Kong. With Professor Dennis Lo and Rossa Chiu, he developed the noninvasive prenatal tests for detecting fetal Down syndrome and other chromosomal aneuploidies. The test has become a standard in prenatal testing and over ten million tests are performed each year across the world. Professor Chan pioneered the development of circulating DNA analysis for cancer detection and led the first large-scale prospective study to evaluate the use of "liquid biopsy" for cancer screening. Using nasopharyngeal cancer as a model, his team showed that plasma DNA analysis is able to detect early asymptomatic cancers and improve survival. This work was selected as one of the ten notable articles published in the New England Journal of Medicine in 2017. Allen is a co-inventor of over 90 patent families and was named one of the "Top 20 Translational Researchers of 2020" by the renowned scientific journal Nature Biotechnology.



Mao Mao 茅矛

Founder and Chief Executive Officer
Pangenia Inc

Dr. Mao Mao is Founder and Chief Executive Officer of SeekIn and TwixBio. He is Adjunct Professor of several universities in Asia. He was Chief Scientific Officer of BGI Genomics responsible for R&D pipeline and oncology business. He was Senior Vice President of Translational Bioscience and Diagnostics responsible for in vitro diagnostics (IVD) product development and clinical lab service at WuXi AppTec. He was President of Asian Cancer Research Group (ACRG), a not-for-profit pharmaceutical industry consortium established jointly by Eli Lilly, Merck and Pfizer to accelerate research and ultimately improve treatment for patients affected with the most commonly diagnosed cancers in Asia. As one of the most senior scientists in Pfizer, he led biomarker and molecular diagnostics efforts at Oncology Research Unit. He managed a lab conducting GCLP-compliant clinical assays and diagnostics research to support Pfizer oncology clinical trials and companion diagnostics. He also worked with the academic and industry partners to generate large scale cancer genomics data. He was Director of Molecular Profiling & Pharmacogenomics at Merck Research Laboratories. He worked on biomarker discovery and coordinating extensive collaborations with academic institutions and industry partners to promote personalized cancer therapy in Asia Pacific region. During his early years with Rosetta/Merck, he made significant contributions to the Ink Jet DNA microarray technology development and subsequent applications. He was one of the inventors of the breast cancer prognosis test (MammaPrint) for the 70 genes identified from the study with his colleagues at Rosetta and the Netherlands Cancer Institute, which became the world's first In Vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire market clearance from the US FDA in 2007. Prior to Rosetta, he was the youngest Associate Professor at Shanghai Second Medical University. As one of the founding members of the National Human Genome Center in Shanghai, he established the first high-throughput DNA sequencing facility and pioneered genome research in China. He was the principal investigator of two National Key Programs of the 9th Five Year Plan in China. He did his doctoral research in studying the mechanism of acute promyelocytic leukemia (APL) differentiation therapy at Shanghai Institute of Hematology under the supervision of Professors Zhu Chen and Zhenyi Wang. During his doctoral study he identified RIG-E, a gene induced by retinoid acid during leukemic cell differentiation, which was recognized as the first novel human gene cloned at a laboratory in China. He also practiced as obstetrician/gynecologist and genetic consultant. He published 100+ articles in the peer-reviewed journals including Nature, Cell, Nature Genetics, Nature Biotechnology and PNAS, and chapters of two books. He is a strong advocate of advancing equitable cancer care through innovation.



Vince Gao 高醇新

Founder, CEO and CSO
Govita

- Founder, CEO & CSO, Govita Tech Ltd, Hong Kong (2016 – current)
Established Biological Pathway Omics (BPO®) and apply it to the research and development of genetic and metabolic testing, AI algorithms for data association, and nutraceutical formulas. Provide healthy longevity products and services to healthcare organizations and people in need. Cultivate talents in biotechnology R&D and successfully commercialize company's products.
- Executive President and CSO, BGI Health, BGI, China (2012 – 15)
Developed multi-omics (genetic, proteomic and metabolomic) detection technologies, health programs and intervention products serving life science and medical institutions. Successfully developed biotech R&D and service teams and lectured globally on the application of multi-omics in healthcare and preventive medicine.
- APAC Sr. Director, China GM, Applied Biosystems | Life Technologies | Sciex, USA 1998 – 2012
Led the development and marketing of molecular assay technologies, reagents and instruments that successfully expanded the market for pharmaceutical research, healthcare and life sciences. Led the company to develop the molecular testing market in the Asia Pacific region, especially in China, with an annual revenue of more than US \$100 million.
- R&D Scientist, Study Director of Drug Metabolism AstraZeneca, USA (1993 – 1998)
Responsible for the clinical and metabolism studies of a breast cancer drug Arimidex. The two-year survival rate for patients taking the drug was 85.4%. The annual revenue of the drug reached \$2B.
- Regenerative Med R&D Scientist, HemaGen, USA (1991 – 1993)
Developed artificial blood products for organ transport, angioplasty, first aid and life support.



Jay Dong

Founder and CEO
UltraDx

Jay Dong has a proven track record of commercial success: having successfully built the China business of a US company from "scratch", to become "the golden standard" of the industry with exceptional revenue growth, AND customer and employee loyalty. Aim to take it to the next level with industry-leading initiatives. Having lived in three countries, the U.S., Singapore and China, Jay Dong is a passionate and humbled business leader with proven track records of delivering results and building teams in multiple global regions. He operates at both strategic and tactical levels and moves between the two objectively as needed.

Jay Dong was a founding general manager of CST (Shanghai) Biological Reagents Company, CST's wholly-owned subsidiary in China that he launched in 2008. CST is a leading life science research company in the areas of enabling biomarker discovery, precision medicine, and companion diagnostics. Previously, he was with Becton Dickinson and Company in the U.S. as a marketing manager and then in Singapore as a business manager. He also co-founded the Precision Medicine and Companion Diagnostic Professional Organization of the Chinese Society of Biotechnology, serving as Secretary General and VP. Jay Dong also served on the board of directors of the Sino-American Biotechnology and Pharmaceutical Professionals Association in San Diego, CST Japan, and the BayHelix Group, as well as a board trustee and Vice Chairman of the Board of the Shanghai American School and its Chair of HR committee and Vice Chair of Finance Committee. Board member of MIT Shanghai Alum.



美國發明專利

CARDIYON™ 倍心安

超早期心血管健康檢測


BOOTH NO. 3E-C18,
3E-C20



取樣方法




指尖血



基因型
(先天遺傳)



心血管健康



表型
(後天環境)



瞭解更多請掃二維碼
Scan QR code for
detailed information

- 預測/預防心血管疾病
- 大幅度降低死亡風險
- 改善心血管健康狀況

2021年全球每天> 56,000人死於心血管疾病
> 56,000 people died of CVDs everyday worldwide in 2021.

80%的心血管疾病若能早期發現，是可以預防疾病發生的
Up to 80% of CVDs are preventable if detected early

几滴血，超早期檢測心血管疾病潛在風險，預防疾病發生
CARDIYON™ Solution can predict and prevent CVDs occurrence

GOVITA
www.govitatech.com

香港沙田香港科學園生物科技中心二座3樓311-312室
311-312, 3/F, Biotech Center Two, HKSTP, Shatin, Hong Kong
Tel: +852 37026860

LOCI'S SQUARE | 基因位點廣場

Start-up Special

Friday, September 15 | 10:00 AM - 17:00 PM (GMT+8)

Building an Innovative Ecosystem for International Start-ups (Sponsored by AstraZeneca)

10:00 - 11:30

How AstraZeneca Can Boost An Innovation Ecosystem in Hong Kong
Ms. Shan Wu, AstraZeneca
Capital Market Review and Healthcare Industry Opportunities
Ms. Rongrong Guo, CICC*

"TOP 5 TO WATCH" PITCHING COMPETITION

11:45 - 17:00

Companies Enrolled in Pitching Competition [List is not in pitching order]

浙江迪福润丝生物科技有限公司
江苏谱新生物医药有限公司
杭州佳量医疗科技有限公司
北京星亢原生物科技有限公司
赛立复
TROMSO NUTRITION TECHNOLOGIES (H.K.) LTD
香港和煦標籤用品有限公司
健顺生物科技（南通）有限公司
Codone Biotechnology
ZenxTag Technology
IntralinksGreater Bay Biotechnology
City U
Provectus Therapeutics
Labware
TUNECT CRO
Alfred Hospital
C2i
A4BEE
META Pharmaceuticals
草姬深圳生命科学行业协会中國科學院
Insighta Limited
北京擎科生物科技股份有限公司
Beijing Tsingke Biotech Co., Ltd.
云舟生物科技（广州）股份有限公司 YUNZHOU BIOSCIENCES (GUANGZHOU) CO., LTD.
廣州南沙新區香港服務中心
Centre for Translational Stem Cell Biology
苏州锐明新药研发有限公司
WWCCPA
HKUST 香港科技大學

*No biography or information was provided before September 01, 2023.

Pitching list was as of September 1, 2023

If you would like to contact these companies, please reach out to chris.pang@hkbio.org.hk

Sponsored by

AstraZeneca 



Shan Wu

**General Manager of Hong Kong and Macau
AstraZeneca China**

Shan Wu is a Chinese-born professional who has made significant contributions to the pharmaceutical industry, particularly in China and Hong Kong. With a background as an organic chemist, she began their career at Johnson & Johnson (J&J), where they gained experience in sales, marketing, and market access roles focused on oncology and haematology. After a successful tenure at J&J, she moved to Roche, further expanding their expertise in the oncology field and contributing to the commercialization of innovative cancer products.

She later returned to J&J during a time when the Chinese government was offering reimbursement for oncology medicines, playing a role in including J&J medicines in the national reimbursement list. With the acquisition of Actelion by J&J, Shan Wu became Actelion's general manager for China, overseeing the integration of the rare disease portfolio and achieving significant growth.

In 2021, she joined AstraZeneca as the manager of the breast cancer franchise in China, leading a team of over 400 professionals. Their leadership approach focused on motivation, direct communication, and clear goal setting. They later assumed the role of general manager for AstraZeneca Hong Kong, reporting directly to the China country manager.

Her contributions to AstraZeneca's success in Hong Kong include a strong portfolio, particularly in oncology, and partnerships that facilitate scientific knowledge transfer. They emphasize the importance of being a first-in-class oncology treatment to gain reimbursement and market access in Hong Kong.

Throughout her career, she has launched various products and has sought to shape the market and drive innovation. Her initiatives highlight the strategic importance of Hong Kong for AstraZeneca, aiming to collaborate with stakeholders, position it as an innovation hub, and act as a gateway between China and the Western world.

Nanobody Discovery & GPCR Service

Dedicated to Support Your Novel NanobodyVHH and GPCR-targeted Drug Development

Customized
Nanobody
Discovery
Service

A

- Alpaca Immunization
- Library Construction
- Library Screening
- Affinity Maturation
- Humanization

Alpaca
Anti-Tag
VHH
Products

B

- Anti-Flag VHH Beads
- Anti-GFP VHH Beads
- Anti-MYC VHH Beads
- Anti-HA VHH Beads
- Anti-mCherry VHH Beads
- Anti-MBP VHH Beads
- Anti-GST VHH Beads

Recombinant
Protein
Production

C

- Bacterial Expression
- Yeast Expression
- Insect Cell Expression
- Mammalian Cell Expression
- GPCR Drug R&D Service
- GPCR Drug Development Support

AlpalifeB Inc.

Toll-free Phone: 1-413-399-9518;

Fax 1-617-336-7451

Office Phone: 1-617-383-9901 Ext 800.

Email: info@alpalifebio.com

Website: www.alpalifebio.com

Address: 299A Washington Street, Woburn, MA 01801 USA





NOVEL EFFECTIVE TREATMENT STRATEGY TO ALZHEIMER'S DISEASE HAS BEEN DEVELOPED

Talengen Institute of Life Sciences/Talengen International Limited is a fully private and independent R&D institute founded in 2015 by a group of dedicated, enthusiastic and professional scientists strived to understand the regulation of hemostasis and thrombolysis, and the functional impacts to the body. Currently, the organization focuses on research and develop novel therapeutical methods against a group of difficult-to-treat diseases, and several therapeutic molecules against a number of unmet medical needs are being developed.

In particular, Talengen has discovered novel treatment strategy and the corresponding compounds to treat Alzheimer's disease. In both pre-clinical and clinical studies, the compound TP02HN106 has shown significant improvement of memory and psychiatric functions within days of treatment. TP02HN106 also shows rapid crossing of the blood-brain barrier, fast decreasing of A β 42 peptide and Tau protein, and also significant improvements of ChAT levels and the lowering of AChE activity. Furthermore, TP02HN106 has demonstrated an excellent safety profile with no adverse events observed.

So far, about 800 patents have been applied for or approved globally, covering a large number of unmet medical needs, treatment methods and territories. The organization welcomes co-development opportunities with international pharmaceutical companies.

Please contact Dr. Li
Tel: +861381 085 0852
Email: jnl@talengen-pharma.com